

# NACC Uniform Data Set (UDS) CODING GUIDEBOOK for Initial Visit Packet

Detailed, annotated explanations of each form on an item-level basis, with instructions, operational definitions, and references

## (Version 2.0, February 2008)

NOTE: Version 2 is NOT the most current version of the UDS forms and is no longer used for data submission. For the most current version, please visit http://www.alz.washington.edu.

This guidebook last modified January 14, 2014

Copyright© 2006, 2008 University of Washington Created and published by the ADC Clinical Task Force (John C. Morris, MD, Chair) and the National Alzheimer's Coordinating Center (Walter A. Kukull, PhD, Director). All rights reserved.

> This publication was funded by the National Institutes of Health through the National Institute on Aging (Cooperative Agreement U01 AG016976)

## The National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) Initial Visit Packet (IVP)

### Introduction

This guidebook contains procedures to be followed when completing the data forms prepared for the Initial Visit Packet of the NACC Uniform Data Set (UDS). The forms and guidebook are published by the National Alzheimer's Coordinating Center (NACC) with the cooperation and approval of the Alzheimer's Disease Centers (ADC) Clinical Task Force.<sup>1</sup>

The Clinical Task Force first convened in October 2002 to begin the process of improving the Minimum Data Set (MDS), which initially consisted of a small set of uniform and standardized data on ADC participants that was contributed by the Alzheimer's Disease Centers (ADCs). Over an 18-month period, the Task Force developed and revised the individual clinical and cognitive variables, and these changes were unanimously approved by the ADC Directors in April 2004. The Task Force then worked closely with NACC to develop the UDS data forms and guidebook to ensure standardization of the criteria and administered items for the database. Throughout this process, the Task Force received helpful input not only from the ADC Directors but also the Clinical Core Leaders, data managers, and many other interested individuals.

The development of the UDS required the adoption of the following principles and assumptions:

- 1. The UDS must contain sufficient data to be useful as a research database, but cannot represent an unacceptable burden to participants or the ADCs. Whenever possible, the UDS capitalizes on criteria, measures, and scales already administered by the majority of ADCs.
- 2. Assessments of all ADC participants, including nondemented controls, will include informant interviews.
- 3. Assessments will be obtained annually whenever possible, so that the UDS is a longitudinal database.

The UDS was the result of that development process, and the system was implemented in September 2005. The new data was intended to expand the MDS; standardize clinical and cognitive data on all ADC participants with uniform clinical assessments and diagnoses; provide data to support current research initiatives (e.g., the NIA's Genetics Initiative); and stimulate and facilitate future collaborative research. It is not hypothesis-driven; rather, it is designed to foster hypothesis-generating studies and, where appropriate, to test specific research questions. The Clinical Task Force subsequently authorized the development of Spanish translations of specific forms to allow the administration of the UDS to non-English speaking participants. A telephone follow-up packet has recently been created to allow data collection for subjects unable to continue in-person assessments, either temporarily or permanently. A milestones form is also required for these subjects.

The Task Force requires that the UDS be administered as a standard protocol, separate from protocols that have been developed for administration at individual ADCs. The ADCs may continue to separately administer their site specific protocols to maintain fidelity with data collected prior to the implementation of the UDS and to address research questions that are not addressed by the UDS.

More recently, the Task Force has developed additional standard assessments and criteria for more advanced stages of AD, as well as for non-AD disorders such as vascular dementia, dementia with Lewy bodies, and frontotemporal lobar degenerations. This current revision of the guidebook (version 2.0) incorporates those changes. Version 2.0 also includes some clarifications and modifications of previous form content and/or data elements.

<sup>&</sup>lt;sup>1</sup> John C. Morris, MD, Washington University (*Task Force Chair*); Helena Chui, MD, University of Southern California; Jeffrey L. Cummings, MD, University of California Los Angeles; Charles DeCarli, MD, University of California Davis; Steven H. Ferris, PhD, New York University; Norman Foster, MD, University of Michigan (inactive); Douglas Galasko, MD, University of California San Diego; Neill Graff-Radford, MD, Mayo Clinic Jacksonville; Elaine Peskind, MD, University of Washington; Sandra Weintraub, PhD, Northwestern University.

## Form Z1: FORM CHECKLIST

The purpose of this form is to report the submission status of all forms in the UDS initial visit packet for each subject.

NACC expects and intends that all UDS forms will be attempted on all subjects, but we realize this may be impossible when the patient is terminally ill, or when there is no informant, or for other reasons. NACC requires that Forms Z1, A1, A5, B4, B9, C1, D1, and E1 be submitted for a subject to be included in the UDS database, even though these forms may include some missing data.

For forms <u>not</u> designated as required, if it is not feasible to collect all or almost all of the data elements for a subject and the ADC therefore decides not to attempt collection of those data, an explanation must be provided. Please indicate this decision below by including the appropriate explanatory code and any additional comments.

KEY: If the specified form was not completed, please enter one of the following codes:

Form	Description	Submitted: Yes No	If not submitted, specify reason (see Key)	Comments (provide if needed)
A1	Subject Demographics	REQUIRED	n/a	n/a
A2	Informant Demographics			
A3	Subject Family History			
A4	Subject Medications			
A5	Subject Health History	REQUIRED	n/a	n/a
B1	Evaluation Form – Physical			
B2	Evaluation Form – HIS and CVD			
B3	Evaluation Form – UPDRS			
B4	Global Staging – CDR <mark>: Standard and</mark> Supplemental	REQUIRED	n/a	n/a
B5 <mark>or B5S</mark>	Behavioral Assessment – NPI-Q			
B6 <mark>or B6S</mark>	Behavioral Assessment – GDS			
B7 <mark>or B7S</mark>	Functional Assessment – FAQ			
B8	Evaluation – Physical/Neurological Exam Findings			
B9	Clinician Judgment of Symptoms	REQUIRED	n/a	n/a
C1 <mark>or C1S</mark>	MMSE and Neuropsychological Battery	REQUIRED	n/a	n/a
D1	Clinician Diagnosis – Cognitive Status and Dementia	REQUIRED	n/a	n/a
E1	Imaging/Labs	REQUIRED	n/a	n/a
Check "	yes" if the specified form was completed	for the subject	t during this visit.	If a form is not designated as

required and is not submitted, enter the appropriate Key code for the reason and provide a written explanation in

95 = Physical problem 96 = Cognitive/behavior problem 97 = Other problem 98 = Verbal refusal

the "Comments" section.

## Form A1: SUBJECT DEMOGRAPHICS

The purpose of this form is to gather basic descriptive information concerning subjects enrolled in the UDS. The form should be completed by the ADC intake interviewer or clinician, and information should be obtained through ADC scheduling records, subject interview, medical records, and proxy informant report (as needed).

Soi	irce of Referral:						
1.	Subject enrolled in NACC MDS:	$\Box$ 1 Yes					
	Check "yes" if the subject was pre Set (MDS).	viously seen in your ADC and was r	eported to the NACC Minimum Data				
2.	Primary reason for coming to ADC:	<ul><li>□ 1 Participate in research study</li><li>□ 2 Clinical evaluation</li></ul>	□ 3 Other ( <i>specify</i> ): □ 9 Unknown				
		s referred, selected/sampled or recru with the ADC or to enroll directly as a					
		s referred by family/friend, self or phy a medical assessment because of c tc.					
	If there is a circumstance not listed enter the reason in the space prov	d which caused the subject to preservided.	nt at the ADC, check number 3 and				
	Check number 9 only if the respor specific response.	ident is unable or unwilling to provid	le information that would allow a more				
3.	Principal referral source:	<ul> <li>1 Self/relative/friend</li> <li>2 Clinician</li> <li>3 ADC solicitation</li> <li>4 Non-ADC study</li> <li>5 Clinic sample</li> </ul>	<ul> <li>□ 6 Population sample</li> <li>□ 7 Non-ADC media appeal (e.g., Alzheimer's Association)</li> <li>□ 8 Other (<i>specify</i>):</li> <li>□ 9 Unknown</li> </ul>				
		-referred or a relative or friend refern direct response to an ADC solicitation	red him/her to the ADC on their own on or recruitment initiative (these				
	Check number 2 if a clinician of ar	ny type referred the subject to the AI	DC for any reason.				
	Check number 3 if the subject pre- subject recruitment effort.	sented primarily as a volunteer in re	sponse to an ADC advertisement or				
	Check number 4 if the subject was subsequently referred to the ADC	s previously enrolled or evaluated in by that study.	a non-ADC study and was				
	Check number 5 if the subject was	s identified through a clinic-based sc	reening or sampling mechanism.				
	Check number 6 if the subject was mechanism.	Check number 6 if the subject was identified through a community-based screening or sampling mechanism.					
		sented primarily as a volunteer in re cheimer's Association or other non-A					
	If the subject was referred to the A number 8 and enter the reason in	DC by means other than described the space provided.	in 1 through 7 above, check				
	Check number 9 only if the respor specific response.	ident is unable or unwilling to provid	le information that would allow a more				

4.	Presumed disease status at enrollment:	<ul><li>□ 1 Case/patient/proband</li><li>□ 2 Control/normal</li></ul>	$\Box$ 3 No presumed disease status
		ssessment staff presumes the disease s s the first or tenth assessment at the Ce	
	Check number 1 if the subject is the	hought to have MCI.	
		s enrolled because s/he was thought to s), regardless of the eventual outcome c	
	Check number 3 if the subject was control (e.g., for population screer	s enrolled and it wasn't yet determined i ning).	if s/he was thought to be a case or
5.	Presumed participation:	$\Box$ 1 Initial evaluation only	□ 2 Longitudinal follow-up planned
	Check number 1 if the subject was planned.	s enrolled for a one-time evaluation, wit	h no subsequent follow-up visits
	Check number 2 if the subject was visits after completing an initial ev	s enrolled with the intent that s/he would aluation.	d make one or more additional
6.	ADC enrollment type:	□ 1 Clinical Core	□ 3 Other ADC Core/project
		□ 2 Satellite Core	□ 4 Center-affiliated/non-ADC
	Check number 1 if the subject is e	enrolled in the Clinical Core at your ADC	<b>)</b> .
	Check number 2 if the subject is e	nrolled at a designated Satellite Core a	t your ADC.
	Check number 3 if the subject is e	enrolled in the ADC, but not through the	Clinical or Satellite Core(s).
	Check number 4 if the subject is p	primarily enrolled in, or supported by, an	nother study (not the ADC).
7.	Subject's month/year of birth:	/	
		nation from the subject (or informant, if cified numerical format (e.g., March 192	
8.	Subject's sex:	□ 1 Male	$\Box$ 2 Female
	Self-explanatory.		
<mark>9.</mark>	Does the subject report being of Hispanic/Latino <u>ethnicity</u> (i.e., having origins from a mainly Spanish-speaking Latin American country), regardless of race?	□ 1 Yes □ 0 No	□ 9 Unknown
	Ask the subject (or informant, if ne Hispanic/Latino.	ecessary) whether the subject considers	s her/his ethnicity to be

	9a. If yes, what are the subject's reported origins?	<ul> <li>□ 1 Mexican/Chicano/ Mexican- American</li> <li>□ 2 Puerto Rican</li> <li>□ 3 Cuban</li> </ul>	<ul> <li>□ 5 Central American</li> <li>□ 6 South American</li> <li>□ 50 Other (<i>specify</i>):</li> </ul>
		$\Box$ 3 Cuban $\Box$ 4 Dominican	99 Unknown
	Ask the subject (or informant, if ne the choices, if required, and allow	ecessary) what s/he considers the subje only one category choice.	ct's origins to be. Read or show
	Check number 1 if the subject rep	ports having origins in Mexico.	
	Check number 2 if the subject rep	ports having origins in Puerto Rico.	
	Check number 3 if the subject rep	ports having origins in Cuba.	
	Check number 4 if the subject rep	ports having origins in the Dominican Re	public.
	Check number 5 if the subject rep Honduras, Nicaragua, or Panama	ports having origins in Belize, Costa Rica a.	a, El Salvador, Guatemala,
	Check number 6 if the subject rep Paraguay, Peru, Uruguay, or Ven	ports having origins in Argentina, Bolivia, ezuela.	Chile, Colombia, Ecuador,
	Check number 50 if the subject reprovided.	eports origins other than those listed, and	d enter the origin in the space
	Check number 99 only if the subje	ect or informant is unable or unwilling to	identify the subject's origins.
10.	What does subject report as her/his race?	<ul> <li>1 White</li> <li>2 Black or African American</li> <li>3 American Indian or Alaska Native</li> </ul>	<ul> <li>□ 4 Native Hawaiian or Other Pacific Islander</li> <li>□ 5 Asian</li> </ul>
			$\Box$ 50 Other ( <i>specify</i> ):
			□ 99 Unknown
		the informant) what s/he considers the s ategory choice. There will be an opportu nd 12.	
	the choices, and allow only one carace categories in questions 11 and	ategory choice. There will be an opportu	nity to record other applicable
	the choices, and allow only one carace categories in questions 11 and Number 4: This includes Native H	ategory choice. There will be an opportune nd 12.	nity to record other applicable loan, or Other Pacific Islander.
	the choices, and allow only one carace categories in questions 11 and Number 4: This includes Native H Number 5: This includes Asian Ind Check number 50 if the subject re	ategory choice. There will be an opportu nd 12. Iawaiian, Guamanian or Chamorro, Sam	nity to record other applicable loan, or Other Pacific Islander. ean, Vietnamese, or Other Asian. I enter the race in the space

11.	What additional race does subject report?	<ul> <li>1 White</li> <li>2 Black or African American</li> <li>3 American Indian or Alaska Native</li> <li>4 Native Hawaiian or Other Pacific Islander</li> </ul>	□ 5 Asian □ 50 Other ( <i>specify</i> ): □ 88 None reported □ 99 Unknown			
	If the subject or informant reports additional race.	an additional race for the subject, check	the box that corresponds to this			
	Numbers 4 and 5: See previous in	nclusion list (question 10).				
	Check number 50 if the subject or informant reports an additional race other than those listed, and ente race in the space provided.					
	Check number 88 if the subject or	informant reports no additional race for	the subject.			
	Check number 99 only if the subje unable or unwilling to identify it.	ct or informant reports the subject as ha	aving an additional race but is			
12.	What additional race, beyond what	□ 1 White	□ 5 Asian			
	was indicated above in questions 10	$\Box$ 2 Black or African American	$\Box$ 50 Other ( <i>specify</i> ):			
	and 11, does subject report?	$\Box$ 3 American Indian or Alaska Native				
		□ 4 Native Hawaiian or Other Pacific	$\square$ 88 None reported			
		Islander	□ 99 Unknown			
	If the subject or informant reports 11, check the box that correspond	another race, in addition to those alread s to this additional race.	y indicated in questions 10 and			
	Numbers 4 and 5: See previous in	nclusion list (question 10).				
	Check number 50 if the subject or race in the space provided.	informant reports an additional race oth	er than those listed, and enter the			
	Check number 88 if the subject or	informant reports no additional race for	the subject.			
	Check number 99 only if the subje unable or unwilling to identify it.	ct or informant reports the subject as ha	aving an additional race but is			
13.	Subject's primary language:	□ 1 English	🗆 6 Japanese			
15.	Subject o primary funguage.	$\square$ 2 Spanish	$\square$ 8 Other primary language			
		$\square$ 3 Mandarin	(specify):			
		$\Box$ 4 Cantonese	□ 9 Unknown			
		$\Box$ 5 Russian				
	Record the language that the subj language that s/he speaks and wr	ect (or informant) considers to be the su tes best.	ibject's main language – i.e., the			
	Check number 8 if the subject or in enter the language in the space pr	nformant reports a primary language oth ovided.	ner than those described, and			
	Check number 9 only if the subjec language.	t or informant is unable or unwilling to id	lentify the subject's primary			

14.	Subject's years of education (report a attempted level is not completed, ent High school/GED = 12; Bachelors de Master's degree = 18; Doctorate = 20	egree $= 16;$	(99 = Unknown)					
	This question refers to achieved educational levels, rather than the number of years it took to complete that level. Use the following to describe achieved educational levels: High school or GED = 12 years, Bachelors degree = 16 years, Master's degree = 18 years, Doctorate = 20 years.							
If the subject hasn't completed a level, enter the total number of years of education completed towa level.								
	subject completed 17.5 years of s master's degree, enter "17". (How degree and that was the intended	school for 8 years and did not earn a di chool and earned a bachelor's degree b rever, if the subject attended school for level of achievement, then enter "16".) " to indicate the achieved educational le	but did not complete an attempted 17.5 years to earn a bachelor's If the <mark>subject</mark> attended school for					
	If the subject or informant is unable	le or unwilling to answer the question, e	nter "99".					
15.	What is the subject's living situation?	<ul> <li>□ 1 Lives alone</li> <li>□ 2 Lives with spouse or partner</li> </ul>	$\Box$ 4 Lives with group $\Box$ 5 Other ( <i>specify</i> ):					
		$\Box$ 3 Lives with relative or friend	□ 9 Unknown					
	Charly the hay far which ever eater							
		gory most accurately describes the subj	-					
	Check number 4 if the subject live	es with a group of related or non-related	persons in a private residence.					
		ving situation is other than those listed, a sing home, <mark>adult family home, or other</mark>						
	Check number 9 only if the subject situation.	ct or informant is unable or unwilling to i	dentify the subject's living					
16.	What is the subject's level of independence?	<ul> <li>□ 1 Able to live independently</li> <li>□ 2 Requires some assistance with complex activities</li> </ul>	<ul> <li>□ 3 Requires some assistance with basic activities</li> <li>□ 4 Completely dependent</li> <li>□ 9 Unknown</li> </ul>					
	do. If the subject or informant indi	gory most accurately describes the leve cates that the subject is able to perform ving situation, the subject is still conside	complex activities but is not doing					
Check number 2 if subject has deterioration in accustomed complex abilities (e.g., paying bill remembering appointments, driving, cooking).								
	Check number 3 if subject has de hygiene).	terioration in accustomed basic abilities	(e.g., eating, dressing, personal					
	Check number 4 if subject is unab	le to perform basic activities of daily livi	<mark>ng.</mark>					
	Check number 9 only if the subject situation.	ct or informant is unable or unwilling to i	dentify the subject's living					

17.	What is the subject's primary type of residence?	<ul> <li>□ 1 Single family residence</li> <li>□ 2 Retirement community</li> <li>□ 3 Assisted living/ boarding home/adult family home</li> </ul>	<ul> <li>□ 4 Skilled nursing facility/ nursing home</li> <li>□ 5 Other (<i>specify</i>):</li> <li>□ 9 Unknown</li> </ul>				
	This type of residence refers to the	e subject's living situation as reported	above.				
	Check number 1 if the subject lives in an apartment, condominium, or house. If the subject's current type of residence is other than those listed, check number 5 and briefly describe in the space provided.						
	Check number 9 only if the subject or informant is unable or unwilling to identify the subject's current type of residence.						
18.	Subject's primary residence zip code (first 3 digits):	(leave blank if unknown)					
		gits of the subject's primary residence provide the information, leave this spa					
19.	Subject's current marital status:	□ 1 Married	$\Box$ 5 Never married				
		$\Box$ 2 Widowed	$\Box$ 6 Living as married				
		□ 3 Divorced	$\Box$ 8 Other ( <i>specify</i> ):				
		$\Box$ 4 Separated	□ 9 Unknown				
		gory most accurately describes the su oplied to either heterosexual or same-					
	Check number 8 if the subject's cuspace provided.	urrent marital status is other than thos	e listed, and briefly describe in the				
	Check number 9 only if the subject	t or informant is unable or unwilling to	o identify the subject's marital status.				
20.	Is the subject left- or right-handed	□ 1 Left-handed	□ 3 Ambidextrous				
	(for example, which hand would s/he normally use to write or throw a ball)?	□ 2 Right-handed	□ 9 Unknown				
	Check the box for whichever cates indicated by the subject or information	gory reflects the hand(s) used most pr ant.	redominantly by the subject, as				
	Check number 9 only if the subject	t or informant is unable or unwilling to	o identify the subject's handedness.				

## Form A2: INFORMANT DEMOGRAPHICS

The purpose of this form is to gather descriptive information concerning the subject's informant. The form should be completed by the ADC intake interviewer or clinician, and information should be obtained through informant interview.

1.	Informant's month/year of birth:	/	
		year of birth in the specified numeric rmant is unable or unwilling to answe	cal format (e.g., March 1920 would be er, enter "99/9999".
2.	Informant's sex:	□ 1 Male	□ 2 Female
	Self-explanatory.		
<mark>3.</mark>	Does the informant report being of Hispanic/Latino <u>ethnicity</u> (i.e., having origins from a mainly Spanish-speaking Latin American country), regardless of race?	□ 1 Yes	□ 0 No □ 9 Unknown
	Ask the informant whether s/he of	considers her/his ethnicity to be Hisp	anic/Latino.
	3a. If yes, what are the informant's reported origins?	<ul> <li>1 Mexican/Chicano/ Mexican- American</li> <li>2 Puerto Rican</li> <li>3 Cuban</li> </ul>	<ul> <li>□ 5 Central American</li> <li>□ 6 South American</li> <li>□ 50 Other (<i>specify</i>):</li> </ul>
		□ 4 Dominican	□ 99 Unknown
	Ask the informant what s/he cor allow only one category choice.	nsiders her/his origins to be. Read or	show the choices, if required, and
	Check number 1 if the informan	t reports having origins in Mexico.	
	Check number 2 if the informan	t reports having origins in Puerto Ric	0.
	Check number 3 if the informan	t reports having origins in Cuba.	
	Check number 4 if the informan	t reports having origins in the Domini	ican Republic.
	Check number 5 if the informan Honduras, Nicaragua, or Panan	t reports having origins in Belize, Cos na.	sta Rica, El Salvador, Guatemala,
	Check number 6 if the informan Paraguay, Peru, Uruguay, or Ve	t reports having origins in Argentina, enezuela.	Bolivia, Chile, Colombia, Ecuador,
	Check number 50 if the informa provided.	nt reports origins other than those lis	ted, and enter the origin in the space
	Check number 99 only if the info	ormant is unable or unwilling to identi	ify her/his origins.

4.	What does informant report as her/his race?	<ul> <li>1 White</li> <li>2 Black or African American</li> <li>3 American Indian or Alaska Native</li> </ul>	<ul> <li>□ 4 Native Hawaiian or Other Pacific Islander</li> <li>□ 5 Asian</li> <li>□ 50Other (<i>specify</i>):</li> <li></li></ul>			
			show the choices, and allow only one able race categories in items 5 and 6.			
	Number 4: This includes Native H	Hawaiian, Guamanian or Chamorr	o, Samoan, or Other Pacific Islander.			
	Number 5: This includes Asian Ir	idian, Chinese, Filippino, Japanes	e, Korean, Vietnamese, or other Asian.			
	Check number 50 if the informant reports a race other than those listed, and enter the race in the space provided. If the informant prefers to report her/his race as multiracial, check number 50 and specify "multiracial".					
	Check number 99 only if the info	rmant is unable or unwilling to ider	ntify her/his race.			
5.	What additional race does	□ 1 White	□ 5 Asian			
	informant report?	$\Box$ 2 Black or African American	$\Box$ 50 Other ( <i>specify</i> ):			
		□ 3 American Indian or Alaska Native	□ 88 None reported			
		□ 4 Native Hawaiian or Other Pacific Islander	□ 99 Unknown			
	If the informant reports an addition	onal race, check the box that corre	sponds to this additional race.			
	Numbers 4 and 5: See previous	inclusion list.				
	Check number 50 if the informan space provided.	t reports an additional race other t	han those listed, and enter the race in the			
	Check number 88 if the informan	t reports no additional race.				
	Check number 99 only if the info	rmant reports an additional race b	ut is unable or unwilling to identify it.			
6.	What additional race, beyond what	□ 1 White	□ 5 Asian			
	was indicated above in questions 4 and 5, does informant report?	$\Box$ 2 Black or African American	$\Box$ 50Other ( <i>specify</i> ):			
	and 5, does mormant report?	□ 3 American Indian or Alaska Native	□ 88 None reported			
		$\Box$ 4 Native Hawaiian or Other	□ 99 Unknown			
		Pacific Islander				
	If the informant reports another n box that corresponds to this addi		dicated in questions 4 and 5, check the			
	Numbers 4 and 5: See previous	inclusion list.				
	Check number 50 if the informan space provided.	t reports an additional race other t	han those listed, and enter the race in the			
	Check number 88 if the informan	t reports no additional race.				
	Check number 99 only if the info	rmant reports an additional race b	ut is unable or unwilling to identify it.			

7.	Informant's years of education (report achieved level using the codes below; if an attempted level is not completed, enter the number of years completed). High school/GED = 12; Bachelors degree = 16; Master's degree = 18; Doctorate = 20 years:							
	This question refers to achieved educational levels, rather than the number of years it took to complete that level. Use the following to describe achieved educational levels: High school or GED = 12 years, Bachelors degree = 16 years, Master's degree = 18 years, Doctorate = 20 years.							
	If the informant hasn't completed level.	a level, enter the total num	ber of years of education completed toward that					
	informant completed 17.5 years attempted master's degree, enter	of school and earned a bac r "17". (However, if the info he intended level of achieve	did not earn a diploma or GED, enter "08". If the helor's degree but did not complete an rmant attended school for 17.5 years to earn a ement, then enter "16".) If the informant attended achieved educational level.					
	If the informant is unable or unw	illing to answer the questior	n, enter "99".					
8.	What is informant's relationship to subject?	<ul> <li>□ 1 Spouse/partner</li> <li>□ 2 Child</li> <li>□ 3 Sibling</li> </ul>	<ul> <li>5 Friend/neighbor</li> <li>6 Paid caregiver/provider</li> <li>7 Other (<i>specify</i>):</li> </ul>					
	Self-explanatory. If the informan briefly describe in the space pro		t is other than those listed, check number 7 and					
9.	Does the informant live with the subject?	□ 1 Yes ( <i>if yes, skip to #10</i> )	□ 0 No					
	Self-explanatory.							
	9a. If no, approximate frequency of in-person visits:	<ul> <li>□ 1 Daily</li> <li>□ 2 At least 3x/week</li> <li>□ 3 Weekly</li> </ul>	<ul> <li>4 At least 3x/month</li> <li>5 Monthly</li> <li>6 Less than once a month</li> </ul>					
	Self-explanatory.							
	9b. If no, approximate frequency of telephone contact:	<ul> <li>□ 1 Daily</li> <li>□ 2 At least 3x/week</li> <li>□ 3 Weekly</li> </ul>	<ul> <li>□ 4 At least 3x/month</li> <li>□ 5 Monthly</li> <li>□ 6 Less than once a month</li> </ul>					
	Self-explanatory.							
10.	Is there a question about the informant's reliability?	□ 1 Yes	□ 0 No					
	The informant's reliability should informant. If there is any reason		opinion from the staff that interacted with the informant, check "yes".					

## Form A3: SUBJECT FAMILY HISTORY

The purpose of this form is to gather descriptive information concerning the subject's family history. The form should be completed by the ADC intake interviewer, and information should be obtained through subject/informant interview.

For the following questions:

<u>Dementia</u> refers to progressive loss of memory and cognition, and may be described as senility, dementia, Alzheimer's Disease, hardening of the arteries, or other causes that compromised the subject's social or occupational functioning and from which they did not recover.

<u>Age at onset</u> refers to the age at which dementia symptoms began, not the age at which the diagnosis was made.

Age should be identified through the clinical history, preferably given by a knowledgeable caregiver or family member. Age of mild memory difficulties of ambiguous significance, consistent with mild cognitive impairment, may not signal age at onset. Memory decline accompanied by symptoms that reflect significant functional change in the individual's abilities, e.g., in judgment, personal finances, home activities, orientation, such that the observed change(s) arouse caregiver concern over safety, determine age at onset of dementia symptoms.

Questions that probe for functional change may include the following:

When did the individual manifest constant forgetfulness, resulting in an inability to manage her/his daily schedule?

When did the individual display a significant failure in judgment in responding to solicitations or subscriptions?

When did the individual manifest a significant change in cooking abilities or other home activities?

When did the individual display a significant change in temporal or physical orientation (confusion regarding dates or locations)?

If you do not know or cannot elicit an exact age at onset, but have a general idea, please approximate to the nearest five-year period.

PARENTS:	a. Year of birth	b. Is the parent still living?	c. If deceased, indicate year of death	d. Does/did this parent have dementia (defined above), as indicated by symptoms, history or diagnosis?			e. If yes, indicate age at onset	
	<mark>(9999=unknown)</mark>	<mark>Yes No Unknown</mark>	<mark>(9999=unknown)</mark>	Yes	No	Unknown	<mark>(999=unknown)</mark>	
1. Mother		$\Box 1 \Box 0 \Box 9$		$\Box 1$	$\Box 0$	□ 9		
2. Father		$\Box 1 \Box 0 \Box 9$		□ 1	$\Box 0$	□ 9		
For column "o that the subje dementia stat For column "e symptoms of	<ul> <li>2. Father 1 0 9 1 0 9 1 0 9 1 0 9</li> <li>Columns "a" thru "c" are self-explanatory.</li> <li>For column "d", if the subject or informant provides no specific evidence (i.e., symptoms, history, or diagnosis) that the subject's mother or father had dementia, check "0". If, after probing, evidence of the parent's dementia status is ambiguous, check "9".</li> <li>For column "e", if the subject's mother and/or father had dementia, enter the age s/he first displayed symptoms of dementia (as described above); do not enter her/his age at the time dementia was diagnosed. If the subject or informant is unable or unwilling to answer, enter "999".</li> </ul>							

#### Please consider blood relatives only.

SIBLINGS:									
3. Is the subject	t a twin?				les	$\Box 0 N$	lo	□9 U	nknown
3a. If yes, ir	ndicate type:				Monozygotic		Dizygotic		nknown
				(	i.e., identical)	(i.	e., fraterna	al)	
Self-explana	atory.								
4. How many f	ull siblings did the	subject	t have?				()	99 = Unknown)	
	umber of siblings		o the su	ubject's bi	ological parents.	If the su	bject/info	rmant is un	able or
	answer, enter "9								
5. For all full s	siblings, indicate th	ie follo <sup>.</sup>	wing: 5b.		5c.		<mark>5d.</mark>		<mark>5e.</mark>
	Year of birth	<mark>ls th</mark>		still living?	If deceased,		this sibling h	nave dementia	<mark>lf yes, indicate</mark>
					indicate year of death		<mark>l above), as i</mark> ns, history o	ndicated by r diagnosis?	<mark>age at onset</mark>
	<mark>(9999=unknown)</mark>	Yes	No	<u>Unknown</u>	<mark>(9999=unknown)</mark>	Yes	No	Unknown	(999=unknown)
Sibling 1		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□ 9	
Sibling 2		$\Box 1$	$\Box 0$	□9		□ 1	$\Box 0$	□9	
Sibling 3		$\Box 1$	$\Box 0$	□9		□ 1	$\Box 0$	□9	
Sibling 4		$\Box 1$	$\Box 0$	□9		□ 1	$\Box 0$	□9	
Sibling 5		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□9	
Sibling 6		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□9	
<mark>Sibling 7</mark>		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□9	
Sibling 8		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□9	
Sibling 9		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□ 9	
Sibling 10		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□9	
Sibling 11		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□9	
Sibling 12		$\Box 1$	$\Box 0$	$\Box 9$		□ 1	$\Box 0$	□9	
Sibling 13		□ 1	$\Box 0$	□9		$\Box 1$	$\Box 0$	□ 9	
Sibling 14		$\Box 1$	$\Box 0$	$\Box 9$		$\Box 1$	$\Box 0$	□9	
Sibling 15		$\Box 1$	$\Box 0$	□9		□ 1	$\Box 0$	□ 9	
Sibling 16		$\Box 1$	$\Box 0$	□9		$\Box 1$	$\Box 0$	□9	
Sibling 17		□ 1		□ 9				□ 9	
Sibling 18		□ 1	$\Box 0$	□9		□ 1	$\Box 0$	□ 9	
Sibling 19		□ 1		□ 9				□ 9	
Sibling 20		□ 1	$\Box 0$	□9			$\Box 0$	□ 9	
<u> </u>	11 (I (C 11	10							

Columns "5a" thru "5c" are self-explanatory.

For column "5d", if the subject or informant provides no specific evidence (i.e., symptoms, history, or diagnosis) that the subject's siblings had dementia, then check "0". If, after probing, evidence of the sibling's dementia status is ambiguous, check "9".

For column "5e", if the subject's siblings had dementia, enter the age the sibling first displayed symptoms of dementia (as described above); do <u>not</u> enter the sibling's age at the time dementia was diagnosed. If the subject or informant is unable or unwilling to answer, enter "999".

#### **CHILDREN:**

6. How many biological children did the subject have?

(99 = Unknown)

Enter the number of children born to the subject. If the subject/informant is unable or unwilling to answer, enter "99".

#### 7. For all biological children, indicate the following:

	7a. Year of birth	<mark>ls the ch</mark>	7b <mark>.</mark> ild still li	iving?	7c. If deceased, indicate year of death	(defined	<mark>l above), as</mark>	ave dementia indicated by or diagnosis?	7e. If yes, indicate age at onset
	<mark>(9999=unknown)</mark>	Yes No		nown	<mark>(9999=unknown)</mark>	Yes	No	Unknown	<mark>(999=unknown)</mark>
Child 1			10 E	∃9		$\Box 1$	$\Box 0$	□9	
Child 2			10 E	∃9		$\Box 1$	$\Box 0$	□9	
Child 3			10 E	∃9		$\Box 1$	$\Box 0$	□ 9	
Child 4			10 E	∃9		$\Box 1$	$\Box 0$	□9	
Child 5			10 E	9		$\Box 1$	$\Box 0$	□9	
Child 6			10 E	9		$\Box 1$	$\Box 0$	□9	
Child 7			10 E	9		$\Box 1$	$\Box 0$	□9	
Child 8			10 E	9		$\Box 1$	$\Box 0$	□9	
Child 9			10 E	9		$\Box 1$	$\Box 0$	□9	
Child 10			10 E	9		$\Box 1$	$\Box 0$	□9	
Child 11			10 E	]9		$\Box 1$	$\Box 0$	□9	
Child 12			10 E	]9		□ 1	$\Box 0$	□9	
Child 13			10 E	]9		$\Box 1$	$\Box 0$	□9	
Child 14			0	] 9		$\Box 1$	$\Box 0$	□9	
Child 15			0	]9		□ 1	$\Box 0$	□9	

#### Columns "7a" thru "7c" are self-explanatory.

**OTHER DEMENTED RELATIVES:** 

For column "7d", if the subject or informant provides no specific evidence (i.e., symptoms, history, or diagnosis) that the subject's biological child had dementia, then check "0". If, after probing, evidence of the child's dementia status is ambiguous, check "9".

For column "7e", if the subject's biological child had dementia, enter the age the child first displayed symptoms of dementia (as described above); do <u>not</u> enter the child's age at the time dementia was diagnosed. If the subject or informant is unable or unwilling to answer, enter "999".

8.		her <mark>demented</mark> rela half siblings), as i						
	If the subject or informant provides no specific evidence (i.e., symptoms, history, or diagnosis) that the subject's other relatives had dementia, enter "0". If, after probing, evidence of the dementia status for other relatives is ambiguous, enter "99".							
<mark>9.</mark>	9. For "other demented relatives" (cousins, aunts, uncles, grandparents, half siblings), indicate the following:							
		9 <mark>a.</mark> <mark>Year of birth</mark>	<mark>ls the</mark>	9t relative	still living?	9 <mark>c.</mark> If deceased, indicate year of death	9 <mark>d.</mark> Indicate age at <mark>onset</mark>	
	(9999=unknown) Yes No Unknown (9999=unknown) (999=unknown)							
Rel	ative 1		□ 1	$\Box 0$	□9			
Rel	ative 2		$\Box 1$	$\Box 0$	□9			

(continued)

	9a. <mark>Year of birth</mark>	<mark>ls the</mark>	9 <mark>b.</mark> Is the relative still living?		9c. If deceased, indicate year of death	9d. Indicate age at onset
	<mark>(9999=unknown)</mark>	Yes	No	Unknown	<mark>(9999=unknown)</mark>	<mark>(999=unknown)</mark>
Relative 3		$\Box 1$	$\Box 0$	□9		
Relative 4		$\Box 1$	$\Box 0$	□9		
Relative 5		$\Box 1$	$\Box 0$	□9		
Relative 6		$\Box 1$	$\Box 0$	□9		
Relative 7		$\Box 1$	$\Box 0$	□9		
Relative 8		$\Box 1$	$\Box 0$	□9		
Relative 9		$\Box 1$	$\Box 0$	□9		
Relative 10		$\Box 1$	$\Box 0$	□9		
Relative 11		$\Box 1$	$\Box 0$	□9		
Relative 12		$\Box 1$	$\Box 0$	□9		
Relative 13		$\Box 1$	$\Box 0$	□9		
Relative 14		$\Box 1$	$\Box 0$	□9		
Relative 15		□ 1	$\Box 0$	□9		
Columns "9a	<mark>" thru "9c" are s</mark>	<mark>elf-exp</mark>	lanato	<mark>ry.</mark>		

For column "9d", enter the age the relative first displayed symptoms of dementia (as described above); do <u>not</u> enter the relative's age at the time dementia was diagnosed. If the subject or informant is unable or unwilling to answer, enter "999".

## Form A4: SUBJECT MEDICATIONS

NOTE: The purpose of this form is to record all prescription medications taken by the subject within the two weeks prior to the current visit. OTC/non-prescription medications need not be reported. [Note: The preceding text came out of a 2009 CTF decision, but due to an oversight it was not immediately added to the form.] This form lists the 100 drugs most commonly reported by subjects at many of the ADCs. The drugs are ordered alphabetically by their generic names and, if applicable, one or more commercial (brand) names are listed in parentheses.

Is the subject currently taking any medications?

 $\Box$  Yes  $\Box$  No

Iosartan (Cozaar)           Iovastatin (Altocor, Mevacor)           medroxyprogesterone (Depo-Provera)           memantine (Namenda)           metformin (Glucophage, Riomet)           mettoprolol (Lopressor, Toprol-XL)           mirtazapine (Remeron)           multivitamin           multivitamin (Glucophage, Riomet)           naproxen (Aleve, Anaprox, Naprosyn)           niacin (Niacor, Nico-400, Nicotinic Acid)           nifedipine (Adalat, Procardia)           nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)           olanzapine (Zyprexa)           omega-3 polyunsaturated fatty acids (Omacor)           partoprazole (Prilosec)           oxybutynin (Ditropan, Urotrol)           partoprazole (Protonix)           potassium chloride (K-Dur 10, K-Lor, Slow-K)           predisone (Deltasone, Orasone)           psyllium (Fiberall, Metamucil)           pyridoxine (Vitamin B6)           quetiapine (Seroquel)           rabeprazole (Aciphex)           raloxifene (Evista)           ranitidine (Zantac)	d03821           d00280           d00284           d00280           d003807           d00134           d04099           d03145           d00314           d003140           d003141           d003142           d00314           d00314           d00314           d00314           d00321           d00322           d004050           d004050           d00328           d004514           d00345           d004220
medroxyprogesterone (Depo-Provera)     memantine (Namenda)     metformin (Glucophage, Riomet)     metoprolol (Lopressor, Toprol-XL)     mirtazapine (Remeron)     multivitamin     multivitamin     multivitamin with minerals     naproxen (Aleve, Anaprox, Naprosyn)     niacin (Niacor, Nico-400, Nicotinic Acid)     nifedipine (Adalat, Procardia)     nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)     olanzapine (Zyprexa)     omega-3 polyunsaturated fatty acids (Omacor)     omeprazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     paroxetine (Paxil, Paxi CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     prevastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     raboyracole (Aciphex)     ranitidine (Zantac)	d00284           d04899           d03807           d00134           d04025           d03140           d003145           d00019           d00314           d00019           d00314           d00314           d00314           d00315           d00328           d00328           d00328           d00328           d00345           d00345           d00345           d00348           d00348           d00412
memantine (Namenda)     metformin (Glucophage, Riomet)     metoprolol (Lopressor, Toprol-XL)     mirtazapine (Remeron)     multivitamin     multivitamin with minerals     naproxen (Aleve, Anaprox, Naprosyn)     niacin (Niacor, Nico-400, Nicotinic Acid)     nifedipine (Adalat, Procardia)     nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)     olanzapine (Zyprexa)     omega-3 polyunsaturated fatty acids (Omacor)     omeprazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     prevastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     ranitidine (Zantac)	d04899           d03807           d00134           d04025           d03140           d03142           d00019           d00314           d00031           d00314           d00314           d00314           d00314           d00321           d00321           d0450           d00425           d00328           d00357           d00345           d00345           d00345           d00348           d00348           d00412           d04220
metformin (Glucophage, Riomet)     metoprolol (Lopressor, Toprol-XL)     mirtazapine (Remeron)     multivitamin     multivitamin with minerals     naproxen (Aleve, Anaprox, Naprosyn)     niacin (Niacor, Nico-400, Nicotinic Acid)     nifedipine (Adalat, Procardia)     nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)     olanzapine (Zyprexa)     omega-3 polyunsaturated fatty acids (Omacor)     omegrazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     raboytace (Evista)	d03807           d00134           d04025           d03145           d00019           d03145           d00019           d03145           d00321           d04050           d04050           d004050           d00325           d00325           d00326           d00348           d00348           d00348           d00348           d00348           d00340           d00143           d00348           d00348           d004514
metoprolol (Lopressor, Toprol-XL)     mirtazapine (Remeron)     multivitamin     multivitamin with minerals     naproxen (Aleve, Anaprox, Naprosyn)     niacin (Niacor, Nico-400, Nicotinic Acid)     nifedipine (Adalat, Procardia)     nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)     olanzapine (Zyprexa)     omega-3 polyunsaturated fatty acids (Omacor)     omegrazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabograzole (Aciphex)     ranitidine (Zantac)	d00134           d04025           d03140           d03145           d00019           d00314           d00314           d00314           d00314           d00314           d00314           d00314           d00325           d00325           d00328           d04514           d00345           d00345           d00345           d00346           d00345           d00346           d00347           d00348           d00340           d003412           d00412
mirtazapine (Remeron)         multivitamin         multivitamin with minerals         naproxen (Aleve, Anaprox, Naprosyn)         niacin (Niacor, Nico-400, Nicotinic Acid)         nifedipine (Adalat, Procardia)         nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)         olanzapine (Zyprexa)         omega-3 polyunsaturated fatty acids (Omacor)         omegrazole (Prilosec)         oxybutynin (Ditropan, Urotrol)         pantoprazole (Portonix)         potassium chloride (K-Dur 10, K-Lor, Slow-K)         pravastatin (Pravachol)         prednisone (Deltasone, Orasone)         psyllium (Fiberall, Metamucil)         pyridoxine (Vitamin B6)         quetiapine (Seroquel)         raborizole (Aciphex)         raloxifene (Evista)	d04025           d03140           d03142           d0019           d00314           d00019           d00314           d00019           d00314           d00314           d00321           d04050           d00325           d00328           d04514           d00345           d00412
multivitamin     multivitamin with minerals     naproxen (Aleve, Anaprox, Naprosyn)     niacin (Niacor, Nico-400, Nicotinic Acid)     nifedipine (Adalat, Procardia)     nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)     olanzapine (Zyprexa)     omega-3 polyunsaturated fatty acids (Omacor)     omegrazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     prevastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabograzole (Aciphex)     ranitidine (Zantac)	d03140           d03145           d00019           d00314           d00011           d00314           d00314           d00011           d00314           d00314           d00321           d00322           d00325           d00325           d00326           d00345           d00345           d00345           d00345           d00346           d00345           d00345           d00345           d00345           d00345           d00345           d00345           d00345           d00422
multivitamin with minerals     naproxen (Aleve, Anaprox, Naprosyn)     niacin (Niacor, Nico-400, Nicotinic Acid)     nifedipine (Adalat, Procardia)     nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)     olanzapine (Zyprexa)     omega-3 polyunsaturated fatty acids (Omacor)     omeprazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     prevastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     raboyrazole (Aciphex)     ranitidine (Zantac)	d03145 d00019 d00314 d00321 d0051 d00320 d00497 d00325 d00328 d004514 d00345 d00345 d00345 d00345 d00345 d00345 d00345 d00345 d00345 d00345 d00340 d00345 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00340 d00320 d00340 d004220 d004220 d004220
naproxen (Aleve, Anaprox, Naprosyn)     niacin (Niacor, Nico-400, Nicotinic Acid)     nifedipine (Adalat, Procardia)     nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)     olanzapine (Zyprexa)     omega-3 polyunsaturated fatty acids (Omacor)     omeprazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     raboyrazole (Aciphex)     ranitidine (Zantac)	d00019 d00314 d00321 d00321 d04050 d00325 d00325 d00328 d00497 d00348 d00348 d00348 d00348 d00348 d00340 d00340 d00350 d01018 d00412 d004220
<ul> <li>niacin (Niacor, Nico-400, Nicotinic Acid)</li> <li>nifedipine (Adalat, Procardia)</li> <li>nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)</li> <li>olanzapine (Zyprexa)</li> <li>omega-3 polyunsaturated fatty acids (Omacor)</li> <li>omeprazole (Prilosec)</li> <li>oxybutynin (Ditropan, Urotrol)</li> <li>pantoprazole (Protonix)</li> <li>parosetine (Paxil, Paxil CR, Pexeva)</li> <li>phenytoin (Dilantin)</li> <li>ptassium chloride (K-Dur 10, K-Lor, Slow-K)</li> <li>prednisone (Deltasone, Orasone)</li> <li>psyllium (Fiberall, Metamucil)</li> <li>pyridoxine (Vitamin B6)</li> <li>quetiapine (Seroquel)</li> <li>raloxifene (Evista)</li> <li>ranitidine (Zantac)</li> </ul>	d00314 d00051 d00321 d04050 d00497 d00325 d00325 d00328 d00348 d00348 d00348 d00348 d00348 d00340 d00340 d00118 d00412 d004220
nifedipine (Adalat, Procardia)         nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)         olanzapine (Zyprexa)         omega-3 polyunsaturated fatty acids (Omacor)         omeprazole (Prilosec)         oxybutynin (Ditropan, Urotrol)         pantoprazole (Protonix)         proxetine (Paxil, Paxil CR, Pexeva)         phenytoin (Dilantin)         potassium chloride (K-Dur 10, K-Lor, Slow-K)         prednisone (Deltasone, Orasone)         psyllium (Fiberall, Metamucil)         pyridoxine (Vitamin B6)         quetiapine (Seroquel)         raloxifene (Evista)	d00051 d00321 d04050 d00497 d00325 d00325 d00328 d04514 d03157 d00143 d00348 d00348 d00348 d00348 d00340 d01018 d00412 d04220
<ul> <li>nitroglycerin (Nitro-Bid, Nitro-Dur, Nitrostat)</li> <li>olanzapine (Zyprexa)</li> <li>omega-3 polyunsaturated fatty acids (Omacor)</li> <li>omeprazole (Prilosec)</li> <li>oxybutynin (Ditropan, Urotrol)</li> <li>pantoprazole (Protonix)</li> <li>paroxetine (Paxil, Paxil CR, Pexeva)</li> <li>phenytoin (Dilantin)</li> <li>potassium chloride (K-Dur 10, K-Lor, Slow-K)</li> <li>pravastatin (Pravachol)</li> <li>prednisone (Deltasone, Orasone)</li> <li>psyllium (Fiberall, Metamucil)</li> <li>pyridoxine (Vitamin B6)</li> <li>quetiapine (Seroquel)</li> <li>rabeprazole (Aciphex)</li> <li>ranitidine (Zantac)</li> </ul>	d00321 d04050 d00497 d00325 d00328 d04514 d03157 d00143 d00345 d00345 d00348 d00345 d00348 d00349 d00340 d01018 d00412 d04220
olanzapine (Zyprexa)         omega-3 polyunsaturated fatty acids (Omacor)         omeprazole (Prilosec)         oxybutynin (Ditropan, Urotrol)         pantoprazole (Protonix)         pantoprazole (Protonix)         phenytoin (Dilantin)         ptoprazole (Pravachol)         prevastatin (Pravachol)         prednisone (Deltasone, Orasone)         psyllium (Fiberall, Metamucil)         pyridoxine (Vitamin B6)         quetiapine (Seroquel)         raloxifene (Evista)         ranitidine (Zantac)	d04050 d00325 d00328 d04514 d03157 d00143 d00345 d00345 d00345 d00345 d00340 d00340 d00340 d00340 d00412 d04220
omega-3 polyunsaturated fatty acids (Omacor)     omeprazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     ranitidine (Zantac)	d00497 d00325 d00328 d04514 d03157 d00143 d00345 d00345 d00348 d00350 d01018 d00412 d04220
omeprazole (Prilosec)     oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     pantoprazole (Protonix)     pantoyratine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     ranitidine (Zantac)	d00325 d00328 d04514 d03157 d00143 d00345 d00348 d00350 d01018 d00412 d04220
oxybutynin (Ditropan, Urotrol)     pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d00328 d04514 d03157 d00143 d00345 d00348 d00350 d01018 d00412 d04220
pantoprazole (Protonix)     paroxetine (Paxil, Paxil CR, Pexeva)     phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d03157 d00143 d00345 d00348 d00350 d01018 d00412 d04220
phenytoin (Dilantin)     potassium chloride (K-Dur 10, K-Lor, Slow-K)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d00143 d00345 d00348 d00350 d01018 d00412 d04220
potassium chloride (K-Dur 10, K-Lor, Slow-K)     pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d00345 d00348 d00350 d01018 d00412 d04220
pravastatin (Pravachol)     prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d00348 d00350 d01018 d00412 d04220
prednisone (Deltasone, Orasone)     psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d00350 d01018 d00412 d04220
psyllium (Fiberall, Metamucil)     pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d01018 d00412 d04220
pyridoxine (Vitamin B6)     quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d00412 d04220
quetiapine (Seroquel)     rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	d04220
rabeprazole (Aciphex)     raloxifene (Evista)     ranitidine (Zantac)	
<ul> <li>raloxifene (Evista)</li> <li>ranitidine (Zantac)</li> </ul>	
□ ranitidine (Zantac)	d04448
	d04261
	d00021
□ risperidone (Risperdal)	d03180
rivastigmine (Exelon)	d04537
<ul> <li>sertraline (Zoloft)</li> <li>simvastatin (Zocor)</li> </ul>	d00880 d00746
	d00740
	d00384
	d00386
	d04294
	d00395
	d03884
	d04113
venlafaxine (Effexor)	d03181
verapamil (Calan, Isoptin, Verelan)	d00048
vitamin E (Aquavite-E, Centrum Singles)	d00405
warfarin (Coumadin, Jantoven)	d00022
zolpidem (Ambien)	d00910
□ Specify:	d
Specify:	d
Specify:	d
Specify:	d
Specify:	d
	d
	d
	d
	d
	valsartan (Diovan)         venlafaxine (Effexor)         verapamil (Calan, Isoptin, Verelan)         vitamin E (Aquavite-E, Centrum Singles)         warfarin (Coumadin, Jantoven)         zolpidem (Ambien)         Specify:         Specify:         Specify:         Specify:

## Form A5: SUBJECT HEALTH HISTORY

The purpose of this form is to record a history of conditions at the current visit as determined by the clinician's best judgment. The form should be completed by the clinician, based on subject/informant report, medical records, and/or observation.

- A condition should be considered "Absent" if it is not indicated by information obtained from informant report, medical records and/or observation.
- A condition should be considered "Recent/Active" if it happened within the last year or still requires active
  management, and is consistent with information obtained from informant report, medical records and/or
  observation.
- A condition should be considered "Remote/Inactive" if it existed or occurred in the past (greater than one year ago) but was resolved or there is no current treatment underway.
- A condition should be considered "Unknown" if there is insufficient information available from informant report, medical records and/or observation.

1.	Ca	rdiovascular disease	Absent	<b>Recent/Active</b>	<b>Remote/Inactive</b>	Unknown
	a.	Heart attack/cardiac arrest	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9
	b.	Atrial fibrillation	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9
	c.	Angioplasty/endarterectomy/stent	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9
	d.	Cardiac bypass procedure	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9
	e.	Pacemaker	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9
	f.	Congestive heart failure	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9
	g.	Other ( <i>specify</i> ):	$\Box 0$	$\Box$ 1	□ 2	□ 9
		Items 1a-1f are self-explanatory.				

For item 1g, ask if the subject has any cardiovascular disease other than those listed. If no, check "0". If yes, record the condition in the space provided and check the appropriate box to specify whether recent/active or remote/inactive.

2.	Cer	rebrovascular disease	Absent	<b>Recent/Active</b>	<b>Remote/Inactive</b>	Unknown
	a.	Stroke	$\Box 0$	$\Box 1$	$\Box 2$	□ 9
		If recent/active or remote/inactive, indicate year(s) in which this occurred:				
		(9999 = Year unknown)	1)	2)	3)	
			4)	5)	6)	
	b.	Transient ischemic attack If recent/active or remote/inactive,				□9
		indicate year(s) in which this occurred: (9999 = Year unknown)	1)	2)	3)	
			4)	5)	6)	
	c.	Other ( <i>specify</i> ):	$\Box 0$	$\Box$ 1	$\Box 2$	□9

Use the following criteria,<sup>1</sup> for stroke and recode either of two categories::

#### Clinical Stroke

Rapidly developing clinical symptoms and/or signs of focal and at times global loss of cerebral function (applied to patients in deep coma and to those with subarachnoid hemorrhage) with symptoms lasting more than 24 hours or leading to death (therefore excluding transient ischemic attacks), and with no apparent cause other than vascular.

Patients are also classified as having an ischemic stroke if they had computed tomographic or magnetic resonance imaging of the brain done within 7 days of onset of symptoms that either identified the symptomatic cerebral infarct or failed to identify an alternative cause of the symptoms.

#### Silent Stroke

Strokes determined by neuroimaging alone for which there is no history nor clinical sign (aka "silent stroke") should be captured by the UDS. This capture will be less than 100% as not all ADC participants have the necessary imaging study available at the time the clinician is completing the UDS form. For this question, a silent stroke, as defined here, would be coded as" remote/inactive," but the year may be unknown unless it can be documented to have occurred between visits, for example as a new MRI finding.

For subquestions a and b, enter each year of occurrence as a 4-digit number. If the event occurred more than once in a given year, make an entry for each occurrence (e.g., if the subject had three strokes in 2006, enter "2006" three times in the spaces provided).

#### TIA

Transient ischemic attack is rapidly developing clinical symptoms and/or signs indicating loss of cerebral function lasting less than 24 hours with no apparent cause other than vascular.

#### <u>Other</u>

If subject has a history of cerebrovascular disease other than those listed, briefly describe the condition in "Other" and check the appropriate box.

<sup>1</sup>Cerebrovascular disease in the community: Results of a WHO Collaborative Study. (S Aho et al., 1980, Bull World Health Org., 58:113-130).

<sup>&</sup>lt;sup>1</sup>Cerebrovascular disease in the community: Results of a WHO Collaborative Study. (S Aho et al., 1980, Bull World Health Org., 58:113-130).

3.	Par	rkinsonian features		Absent	<b>Recent/Active</b>	Unknown			
	a.	Parkinson's disease		$\Box 0$	$\Box$ 1	□ 9			
		If recent/active, indicate year of diagnosis:	= Year unknown)						
	b.	Other Parkinsonism disorder							
		If recent/active, indicate year of diagnosis:				-			
		(9999 = Year unknown)							
4.	Otl	her neurologic conditions	Absent	<b>Recent/Active</b>	<b>Remote/Inactive</b>	Unknown			
	a.	Seizures	$\Box 0$	$\Box$ 1	$\Box 2$	$\Box$ 9			
	b.	Traumatic brain injury							
		<ol> <li>with brief loss of consciousness (&lt; 5 minutes)</li> </ol>	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
		<ul><li>2) with extended loss of</li></ul>							
		consciousness ( $\geq$ 5 minutes)	$\Box 0$	$\Box 1$	$\Box 2$	□9			
		3) with chronic deficit or dysfunction	$\Box 0$	$\Box$ 1	$\Box 2$	$\Box$ 9			
	c.	Other ( <i>specify</i> ):	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
		Self-explanatory. For item 4b3, check nu	mber 1 or 2 if	sustained neuro	logical impairment	resulted from			
		the head injury.							
		If subject has a history of neurologic cond	dition other the	an those listed, b	oriefly describe the	condition in			
		"Other" and check the appropriate box.							
5.	Me	edical/metabolic conditions	Absent	<b>Recent/Active</b>	Remote/Inactive	Unknown			
	a.	Hypertension	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
	b.	Hypercholesterolemia	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
	c.	Diabetes	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
	d.	B12 deficiency	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
	e.	Thyroid disease	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
	f.	Incontinence – urinary	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
	g.	Incontinence – bowel	$\Box 0$	$\Box$ 1	$\Box 2$	□ 9			
		Self-explanatory.							
6.	De	pression		No	Yes	Unknown			
	Inc	clude depressive disorders for which a clini	ician was con	sulted, whether c	or not treatment (be	ehavioral or			
		ug) was received. Depression includes maj							
		sorders, dysthymic disorders, and other mo views, clinicians' opinion, or whether the su							
		Active within past 2 years							
	a.	· ·							
		Check "yes" if the subject has had a depr there have been no episodes of depressi							
		subject/informant report and/or medical re	ecords, it can						
		occurred within the past two years, check	k "unknown".						
	b.	Other episodes (prior to 2 years)			□ 1	□9			
		Check "yes" if episodes of depression oc							
		depression prior to two years ago, check							
		records, it cannot be determined whether "unknown".	depression c	occurred prior to t	ine past two years	, Check			

7.	Sul	ostan	ce abuse and psychiatric disorders				
	a.		ostance abuse – alcohol	Absent	<b>Recent/Active</b>	<b>Remote/Inactive</b>	Unknown
		1)	Clinically significant impairment occurring over a 12-month period manifested in one of the following: work, driving, legal or social.	$\Box 0$	□ 1	□ 2	□9
			Self-explanatory.				
	b.	Cig	arette smoking history		No	Yes	Unknown
			s section refers to cigarette smoking arding chewing tobacco, snuff, etc., p				rmation
		1)	Has subject smoked within last 30 days?		□ 0	□ 1	□ 9
			Self-explanatory.				
		2)	Has subject smoked more than 100 cigarettes in her/his life?		□ 0	□ 1	□ 9
			If the subject has not smoked more "N/A" for each of the remaining three			e, check "no" and	then indicate
		3)	Total years smoked: $(88 = N/2)$	A; 99 = Unknow	n)		
			Self-explanatory.				
		4)	Average number of packs/day smoked: $\Box$ 1 1 cigarette $- < \frac{1}{2}$ pac $\Box$ 2 $\frac{1}{2} - < 1$ pack $\Box$ 3 $1 - < \frac{1}{2}$ pack	ck	$\Box 4  1\frac{1}{2} - < 2 \text{ packs}$ $\Box 5 \geq 2 \text{ packs}$ $\Box 8  N/A$	s □9 U	Inknown
			Check the appropriate box to indicat while s/he was a smoker. Check nur available information or observation	mber 9 only i			
		5)	If subject quit smoking, specify age when last smoked (i.e., quit): $(888 = N/A)$	; 999 = Unknow	n)		
			Self-explanatory.				
	c.		er abused substances	Absent	<b>Recent/Active</b>	Remote/Inactive	Unknown
		1)	Clinically significant impairment occurring over a 12-month period manifested in one of the following: work, driving, legal or social.		□ 1		□ 9
		lf r	ecent/active or remote/inactive, specify a				
			If number 1 or 2 is checked, briefly o	describe the	other abused subst	ance(s) in the spa	ace provided.
	d.	•	chiatric disorders ecent/active or remote/inactive, specify d	□ 0 isorder(s):	□ 1		□ 9
			umber 1 or 2 is checked, briefly desc tem 6 above), in the space provided.	ribe the psyc	chiatric disorder(s),	other than depres	ssion (reported

## Form B1: EVALUATION FORM – PHYSICAL

The purpose of this form is to provide a record of physical evaluation of the subject for the current visit. The form should be completed by the clinician, based on information obtained through examination.

	SUBJECT PHYSICAL MEASURE	MENTS		
1.	Subject height (inches): (99.9 = un	known)•		
	If height cannot be measured (e.g., subject is con- unable to stand), enter "99.9".	fined to a whe	elchair or	
2.	Subject weight (lbs.): (999 = unit	known)	_	
	If weight cannot be measured, enter "999".			
3.	Subject blood pressure (sitting) (999/999 = uni	known)	_/	
	If blood pressure cannot be obtained, enter "999" diastolic values.	for both systol	ic and	
4.	Subject resting heart rate (pulse) (999 = unit	known)	_	
	If pulse cannot be obtained, enter "999".			
ΑΓ	DITIONAL PHYSICAL OBSERVATIONS	Yes	No	Unknown
5.	Without corrective lenses, is the subject's vision functionally normal?			□ 9
	Check "no" if any functional impairment exists (red such as reading, watching television).	duced ability to	o do everyday a	activities
6.	Does the subject usually wear corrective lenses?	$\Box$ 1	$\Box 0$	□ 9
	6a. If yes, is the subject's vision functionally normal <u>with</u> corrective lenses?		$\Box 0$	□ 9
	Check "no" if any functional impairment exists (red such as reading, watching television).	duced ability to	o do everyday a	activities
7.	Without a hearing aid(s), is the subject's hearing functionally normal?	□ 1		□9
	Check "no" if any functional impairment exists (red such as listening to the radio or television, talking			activities
8.	Does the subject usually wear a hearing aid(s)?	□ 1	$\Box 0$	□ 9
	8a. If yes, is the subject's hearing functionally normal <u>with</u> a hearing aid(s)?	□ 1	$\Box 0$	□9
	Check "no" if any functional impairment exists (red such as listening to the radio or television, talking			activities

## Form B2: EVALUATION FORM – HIS and CVD

The form should be completed by the clinician or other trained health professional, based on information obtained from history/physical/neurological exam and/or medical records.

HA	ACHINSKI ISCHEMIC SCORE <sup>1</sup>			
an	ase complete the following scale using information obtained from history/p d/or medical records. Circle the appropriate value to indicate if a specific ite			
the	patient) or absent.	Present	Absent	
1.	Abrupt onset (re: cognitive status)	2	0	
2.	Stepwise deterioration (re: cognitive status)	1	0	
3.	Somatic complaints	1	0	
4.	Emotional incontinence	1	0	
5.	History or presence of hypertension	1	0	
6.	History of stroke	2	0	
7.	Focal neurological symptoms	2	0	
8.	Focal neurological signs	2	0	
	Circle the appropriate value to indicate if a specific item is presen <u>patient</u> ) or absent.	t ( <u>characteristic o</u>	<u>f the</u>	
	Items 7 and 8 refer to symptoms and signs with cerebrovascular of due to stroke would be included here. Aphasia such as Primary P not be reflected in the Hachinski Ischemic Score.			
9.	Sum all circled answers for a Total Score:			
	Calculate the sum of values for all circled answers and enter the t provided. If any question remains unanswered, then a valid score			
CI	REBROVASCULAR DISEASE	Yes	No	N/A
<mark>10</mark>	Using your best judgment, do you believe that cerebrovascular disease (CVD) is contributing to the cognitive impairment?			
	This question seeks to get your best clinical judgment regarding the subject. Recent data suggest that even asymptomatic CVD n individuals without evidence of Alzheimer's disease. The role of a Alzheimer's disease is less clear, but likely to be less relevant. The Examples include an asymptomatic thalamic lacune; this is likely	nay play a role in asymptomatic CV herefore, we are s	cognitive impa D in patients v seeking your ju	airmen vith udgme
	lacune in the basal ganglia may not be. In general, cortical infarc cognitive disability occurs prior to the onset of AD or occurs in the	tions impair cogn		

<sup>&</sup>lt;sup>1</sup> Rosen Modification of Hachinski Ischemic Score (Ann Neurol 7:486-488, 1980). Copyright© John Wiley & Sons, Inc. Reproduced by permission.

onset of cognitive impairment?		<mark>□ 0</mark>	<mark>□ 8</mark>
Temporal relationship is defined in two ways. First, the stroke occurr in cognition or transition from one state of cognitive ability to a lower NL $\rightarrow$ MCI or MCI $\rightarrow$ AD). Second, if the stroke is associated with co question should be answered "no" if there is a history of distant strok preserved for 6 months or longer.	state of cogn gnitive declin	itive ability (e. e within 3-6 n	<mark>.g.,</mark> nonths. This
If no stroke, then check "N/A".			
12. Is there imaging evidence which supports that CVD is contributing to the cognitive impairment?	<mark>□ 1</mark>		
12a. If yes, indicate which imaging evidence was found:			
1) Single strategic infarct	🗆 1	<mark>□ 0</mark>	
2) Multiple infarcts	🗆 1	<mark>□ 0</mark>	
3) Extensive white matter hyperintensity	🗆 1	<mark>□ 0</mark>	
4) Other ( <i>specify</i> ):	🗆 1	<mark>□ 0</mark>	
This can be a challenging question. We are looking for evidence of s non-strategic areas are not likely to be relevant. If there are multiple four in number, unless they involve strategic structures (e.g., thalam Cortical involvement is generally considered sufficient, even with a s considered strategic). Multiple cortical infarctions should lead you to Extensive white matter hyperintensities are considered to involve over would be equivalent to a 7 or 8 on the CHS qualitative scale. Extension considered as contributing to MCI, but caution should be taken with	lacunes, they us, hippocam ingle infarct (i consider pure er 25% of con ive white mat	should be gropus, frontal lo .e., this would vascular der tical white ma ter disease sh scular diagnos	eater than be). I be nentia. Itter. This nould be

## Form B3: EVALUATION FORM – UNIFIED PARKINSON'S DISEASE RATING SCALE (UPDRS<sup>1</sup>) – MOTOR EXAM

This form should be completed by the clinician or other trained health professional, based on neurological exam of the subject. Choose the most accurate description of the subject's current condition for each neurological aspect.

	[Optional] If the clinician completes the UPDRS examination and determines all items are normal, check this box and end form here.							
	This box may be checked in lieu of all other items below if the clinician completes the subject exam and determines that all functions are normal.							
1.	Speech	$\Box 0$	Normal.	□ 3	Marked impairment, difficult to understand.			
		□ 1	Slight loss of expression, diction and/or volume.	□ 4 □ 8	Unintelligible. Untestable ( <i>specify reason</i> ):			
		□ 2	Monotone, slurred but understandable; moderately impaired.					
2.	Facial	$\Box 0$	Normal.	$\Box$ 3	Moderate hypomimia; lips parted some of the time.			
	expression	ression 1 Minimal hypomimia, could be normal "poker face".		□ 4	Masked or fixed facies with severe or complete loss of facial expression; lips parted <sup>1</sup> / <sub>4</sub> inches or more.			
		□ 2	Slight but definitely abnormal diminution of facial expression.		Untestable (specify reason):			
3.	3. Tremor at rest							
3a.	Face, lips,	$\Box 0$	Absent.	□ 3	Moderate in amplitude and present most of the			
	chin	□ 1	Slight and infrequently present.		time.			
		$\Box 2$		□ 4				
			moderate in amplitude, but only intermittently present.		Untestable (specify reason):			
3b.	Right	$\Box 0$	Absent.	□ 3	Moderate in amplitude and present most of the			
	hand	$\Box 1$	Slight and infrequently present.		time.			
		$\Box 2$	Mild in amplitude and persistent; or	$\Box 4$	Marked in amplitude and present most of the time.			
			moderate in amplitude, but only intermittently present.		Untestable (specify reason):			
3c.	Left	$\Box 0$	Absent.	□ 3	Moderate in amplitude and present most of the			
	hand	$\Box 1$	Slight and infrequently present.		time.			
		$\Box 2$	Mild in amplitude and persistent; or	□ 4	Marked in amplitude and present most of the time.			
			moderate in amplitude, but only intermittently present.		Untestable (specify reason):			
3d.	Right foot	$\Box 0$	Absent.	□ 3	Moderate in amplitude and present most of the			
		$\Box 1$	Slight and infrequently present.	<i>.</i>	time.			
		$\Box 2$	Mild in amplitude and persistent; or	$\Box 4$	Marked in amplitude and present most of the time.			
			moderate in amplitude, but only intermittently present.		Untestable (specify reason):			

<sup>&</sup>lt;sup>1</sup>Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163, 293-304. Reproduced by permission of the author.

3e.	Left	$\Box 0$	Absent.	□ 3	Moderate in amplitude and present most of the
	foot	$\Box 1$	Slight and infrequently present.		time.
		$\Box 2$	Mild in amplitude and persistent; or	$\Box 4$	1 1
			moderate in amplitude, but only intermittently present.		Untestable ( <i>specify reason</i> ):
4.	_		tremor of hands		
4a.	Right hand		Absent.	□3	Moderate in amplitude with posture holding as well as action.
	nana		Slight; present with action.	□ 4	Marked in amplitude; interferes with feeding.
		$\Box 2$	Moderate in amplitude, present with action.		Untestable ( <i>specify reason</i> ):
4b.	Left	$\Box 0$	Absent.	□ 3	Moderate in amplitude with posture holding as well
	hand	$\Box 1$	Slight; present with action.		as action.
		$\Box 2$	Moderate in amplitude, present with	□ 4	I , U
			action.		Untestable ( <i>specify reason</i> ):
5.	Rigidity (jud ignored)	lged of	n passive movement of major joints with pa	atient r	elaxed in sitting position; cogwheeling to be
5a.	Neck	$\Box 0$	Absent.	$\Box$ 3	Marked, but full range of motion easily achieved.
		$\Box 1$	Slight or detectable only when activated	$\Box 4$	Severe; range of motion achieved with difficulty.
			by mirror or other movements.		Untestable (specify reason):
			Mild to moderate.		
5b.	Right upper		Absent.		Marked, but full range of motion easily achieved.
	extremity	$\Box 1$	Slight or detectable only when activated by mirror or other movements.		Severe; range of motion achieved with difficulty.
		$\Box 2$	Mild to moderate.		Untestable ( <i>specify reason</i> ):
5c.	Left upper	$\Box 0$	Absent.	□ 3	Marked, but full range of motion easily achieved.
	extremity	$\Box$ 1	Slight or detectable only when activated	□ 4	Severe; range of motion achieved with difficulty.
			by mirror or other movements.		Untestable ( <i>specify reason</i> ):
		$\Box 2$	Mild to moderate.		
5d.	Right	$\Box 0$	Absent.	$\Box$ 3	Marked, but full range of motion easily achieved.
	lower extremity	$\Box 1$	Slight or detectable only when activated	$\Box 4$	Severe; range of motion achieved with difficulty.
	extremity		by mirror or other movements.		Untestable (specify reason):
_	<b>T</b> 0.1		Mild to moderate.		
5e.	Left lower extremity		Absent.		Marked, but full range of motion easily achieved.
	extremity	$\Box 1$	Slight or detectable only when activated by mirror or other movements.	$\Box 4$	Severe; range of motion achieved with difficulty.
		$\Box 2$	Mild to moderate.		Untestable ( <i>specify reason</i> ):
6.	Finger taps		t taps thumb with index finger in rapid suce	cessior	n)
ба.	Right		Normal.	□ 3	
	hand	$\Box$ 1	Mild slowing and/or reduction in		movements or arrests in ongoing movement.
			amplitude.	$\Box 4$	Can barely perform the task.
		□ 2	Moderately impaired; definite and early fatiguing; may have occasional arrests in movement.		Untestable ( <i>specify reason</i> ):

6b.	Left	$\Box 0$	Normal.	□ 3	
	hand	$\Box 1$	Mild slowing and/or reduction in amplitude.	□ 4	movements or arrests in ongoing movement. Can barely perform the task.
		$\Box 2$	Moderately impaired; definite and early		Untestable ( <i>specify reason</i> ):
			fatiguing; may have occasional arrests		
			in movement.		
7.	Hand mover	nents (	patient opens and closes hands in rapid suc	ccessio	n)
7a.	Right hand	$\Box 0$	Normal.	□ 3	
	nanu	$\Box 1$	Mild slowing and/or reduction in amplitude.	□ 4	movements or arrests in ongoing movement. Can barely perform the task.
		$\Box 2$	Moderately impaired; definite and early		Untestable ( <i>specify reason</i> ):
			fatiguing; may have occasional arrests in movement.		
76	Left		Normal.		Sourcely impaired, frequent hesitation in initiating
70.	hand	$\Box 1$			Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement.
			amplitude.	□ 4	Can barely perform the task.
		$\Box 2$			Untestable (specify reason):
			fatiguing; may have occasional arrests in movement.		
8.	Danid altarn	otina r	novements of hands (proposition supination	mouar	nents of hands, vertically and horizontally, with as
0.	-	-	as possible, both hands simultaneously)	moven	nents of hands, vertically and horizontally, with as
8a.	Right	$\Box 0$	Normal.	□ 3	Severely impaired; frequent hesitation in initiating
	hand	$\Box 1$	e		movements or arrests in ongoing movement.
			amplitude. Moderately impaired; definite and early		Can barely perform the task. Untestable ( <i>specify reason</i> ):
			fatiguing; may have occasional arrests		
			in movement.		
8b.	Left hand	$\square 0$	Normal.		Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement.
	nanu	$\Box 1$	Mild slowing and/or reduction in amplitude.	□ 4	
		$\Box 2$	Moderately impaired; definite and early		Untestable ( <i>specify reason</i> ):
			fatiguing; may have occasional arrests		
			in movement.		
9.	Leg agility ( inches)	patien	t taps heel on the ground in rapid successio	on, pick	ing up entire leg; amplitude should be at least 3
9a.	Right leg	$\Box 0$	Normal.		Severely impaired; frequent hesitation in initiating
		$\Box 1$	Mild slowing and/or reduction in		movements or arrests in ongoing movement.
			amplitude. Moderately impaired; definite and early	$\square 4$	Can barely perform the task.
			fatiguing; may have occasional arrests in movement.		Untestable ( <i>specify reason</i> ):
9b.	Left leg	$\Box 0$	Normal.	□ 3	Severely impaired; frequent hesitation in initiating
		$\Box 1$	Mild slowing and/or reduction in	_ <i>.</i>	movements or arrests in ongoing movement.
			amplitude.		Can barely perform the task.
		□2	Moderately impaired; definite and early fatiguing; may have occasional arrests in movement.		Untestable ( <i>specify reason</i> ):

at st	Arising from chair (patient ttempts to rise from a traight-backed chair, with rms folded across chest)	$\Box 0$ $\Box 1$ $\Box 2$	Normal. Slow; or may need more than one attempt. Pushes self up from arms of seat.	□ 4	Tends to fall back and may have to try more than one time, but can get up without help. Unable to arise without help. Untestable ( <i>specify reason</i> ):
11. P	Posture	$\Box 0$ $\Box 1$ $\Box 2$	Normal. Not quite erect, slightly stooped posture; could be normal for older person. Moderately stooped posture, definitely abnormal; can be slightly leaning to one side.	□ 3 □ 4 □ 8	Severely stooped posture with kyphosis; can be moderately leaning to one side. Marked flexion with extreme abnormality of posture. Untestable ( <i>specify reason</i> ):
12. G	Gait	□ 0 □ 1 □ 2	Normal. Walks slowly; may shuffle with short steps, but no festination (hastening steps) or propulsion. Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or propulsion.	□ 3 □ 4 □ 8	Severe disturbance of gait requiring assistance. Cannot walk at all, even with assistance. Untestable ( <i>specify reason</i> ):
tc di pr pr oj	Posture stability (response o sudden, strong posterior displacement produced by sull on shoulders while vatient erect with eyes open and feet slightly part; patient is prepared)	□ 0 □ 1 □ 2	Normal erect. Retropulsion, but recovers unaided. Absence of postural response; would fall if not caught by examiner.	□ 3 □ 4 □ 8	
hy sl de ai	Body bradykinesia and hypokinesia (combining lowness, hesitancy, lecreased arm swing, small mplitude, and poverty of movement in general)	□ 0 □ 1 □ 2	None. Minimal slowness, giving movement a deliberate character; could be normal for some persons; possibly reduced amplitude. Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, some reduced amplitude.		Moderate slowness, poverty or small amplitude of movement. Marked slowness, poverty or small amplitude of movement. Untestable ( <i>specify reason</i> ):

## Form B4: GLOBAL STAGING – CLINICAL DEMENTIA RATING (CDR): STANDARD AND SUPPLEMENTAL

The form should be completed by the clinician or other trained health professional, based on informant report and neurological exam of the subject. In the extremely rare instances when no informant is available, the clinician or other trained health professional must complete both the standard and supplemental versions of the CDR utilizing all other available information and her/his best clinical judgment. In support of the Uniform Data Set (UDS), NACC asked the Washington University ADC to create a CDR (standard version) training site for ADC personnel based on the training currently offered for staff working on the Alzheimer's Disease Cooperative Study (ADCS) trials. The UDS CDR Training Application (standard) may be accessed online at http://alzheimer.wustl.edu/cdr/Application/Step1.htm.

#### **SECTION 1: STANDARD CDR**

Use all information and make the best judgment. Score each category as independently as possible. Mark in only one box for each category, rating impairment as decline from the person's usual level due to cognitive loss alone, not impairment due to other factors such as physical handicap or depression. Occasionally, the evidence is ambiguous and the clinician's best judgment is that a category could be rated in either one of two adjacent boxes, such as mild (1) or moderate (2) impairment. In that situation, the standard procedure is to check the box of greater impairment.

Aphasia is taken into account by assessing both language and non-language function in each cognitive category. If aphasia is present to a greater degree than the general dementia, the subject is rated according to the general dementia. Supply evidence of non-language cognitive function.

#### Standard CDR Sum of Boxes

Calculate the sum of values for all answers and enter the total score in the space provided.

#### Standard Global CDR

The standard global CDR is derived from the scores in each of the six categories ("box score") as follows:

- Memory (M) is the primary category and all others are secondary.
- CDR = M if at least three secondary categories are given the same score as memory. Whenever three
  or more secondary categories are given a score greater or less than the memory score, CDR = score
  of majority of secondary categories on whichever side of M has the greater number of secondary
  categories. However, when three secondary categories are scored on one side of M and two
  secondary categories are scored on the other side of M, then CDR = M.
- When M = 0.5, CDR = 1 if at least three of the other categories are scored 1 or greater. If M = 0.5, then CDR cannot be 0; it can only be 0.5 or 1.
- If M = 0, then CDR = 0 unless there is impairment (0.5 or greater) in two more secondary categories, in which case CDR = 0.5.

Although applicable to most AD situations, these rules do not cover all possible scoring combinations. Unusual circumstances that occasionally occur in AD, and may be expected in non-Alzheimer's dementia as well, are scored as follows:

- With ties in the secondary categories on one side of M, choose the tied scores closest to M for CDR (e.g., if M and another secondary category = 3, two secondary categories = 2, and two secondary categories = 1, then CDR = 2).
- 2) When only one or two secondary categories are given the same score as M, CDR = M as long as no more than two secondary categories are on either side of M.
- 3) When M = 1 or greater, CDR cannot be 0; in this circumstance, CDR = 0.5 when the majority of secondary categories are 0.

The CDR scoring algorithm can be accessed online at <u>http://www.biostat.wustl.edu/~adrc/cdrpgm/index.html</u>.

## **SECTION 2: SUPPLEMENTAL CDR**

In addition to the factors investigated within the standard CDR, two additional constructs, "Behavior, Comportment and Personality" and "Language", have been appended as the UDS Supplemental CDR, which will aid in the identification subjects with Frontotemporal Dementia and/or Primary Progressive Aphasia, respectively. Due to the specialized nature of these, instructions for the scoring of each item are outlined below.

#### **Behavior, Comportment and Personality:**

This item should be completed by a clinician or other trained health professional who is skilled in the assessment of FTLD, based on informant report and a review of the subject's cognitive, functional and behavioral status. This domain is intended to assess changes in personality, aberrant behaviors and changes in interpersonal relationships. The kinds of specific issues that might fall under these rubrics include: loss of insight, disinhibition, apathy, social withdrawal and disengagement, emotional lability, easy distractibility, reduced empathy for the feelings of others, impulsivity, and changes in eating habits and table manners. A key element of each of these is the degree to which these behaviors impact interpersonal relationships.

#### Language:

This item should be completed by a clinician or other trained health professional who is well versed in aphasia and aphasic disorders, based on information derived from the informant and also from clinical assessment of the patient's language functions in the course of the clinical interview and the mental status examination. This domain is intended to assess changes in language. The components of language that are primarily of interest include: spontaneous speech, auditory comprehension, object naming, reading and writing. Using these in combination, the goal is to assess the subject's ability to create and understand various forms of information. The rate at which these are generated or comprehended is also of interest.

#### CLINICAL DEMENTIA RATING (CDR): STANDARD AND SUPPLEMENTAL

#### SECTION 1: STANDARD CDR<sup>1</sup>

			IMPAIRMENT		
Please enter scores below	None 0	Questionable 0.5	Mild 1	Moderate 2	Severe 3
1. MEMORY ·	No memory loss, or slight inconsistent forgetfulness.	Consistent slight forgetfulness; partial recollection of events; "benign" forgetfulness.	Moderate memory loss, more marked for recent events; defect interferes with everyday activities.	Severe memory loss; only highly learned material retained; new material rapidly lost.	Severe memory loss; only fragments remain.
2. ORIENTATION	Fully oriented.	Fully oriented except for slight difficulty with time relationships.	Moderate difficulty with time relationships; oriented for place at examination; may have geographic disorientation elsewhere.	Severe difficulty with time relationships; usually disoriented to time, often to place.	Oriented to person only.
3. JUDGMENT & PROBLEM SOLVING 	Solves everyday problems, handles business & financial affairs well; judgment good in relation to past performance.	Slight impairment in solving problems, similarities, and differences.	Moderate difficulty in handling problems, similarities, and differences; social judgment usually maintained.	Severely impaired in handling problems, similarities, and differences; social judgment usually impaired.	Unable to make judgments or solve problems.
4. COMMUNITY AFFAIRS ·_	Independent function at usual level in job, shopping, volunteer and social groups.	Slight impairment in these activities.	Unable to function independently at these activities, although may still be engaged in some; appears normal to casual inspection.	No pretense of independent function outside the home; appears well enough to be taken to functions outside the family home.	No pretense of independent function outside the home; appears too ill to be taken to functions outside the family home.
5. HOME & HOBBIES	Life at home, hobbies, and intellectual interests well maintained.	Life at home, hobbies, and intellectual interests slightly impaired.	Mild but definite impairment of function at home; more difficult chores abandoned; more complicated hobbies and interests abandoned.	Only simple chores preserved; very restricted interests, poorly maintained.	No significant function in the home.
6. PERSONAL CARE 0	Fully capab	le of self-care (= 0).	Needs prompting.	Requires assistance in dressing, hygiene, keeping of personal effects.	Requires much help with personal care; frequent incontinence.
7	STANDARD CDR SUN		-		
8	<mark>STANDARD</mark> GLOBAL	CDR			

#### SECTION 2: SUPPLEMENTAL CDR

				IMPAIRMENT		
	Please enter	None	Questionable	Mild	Moderate	Severe
	scores below	0	0.5	1	2	3
<mark>9.</mark>		Socially appropriate	Questionable changes in	Mild but definite changes	Moderate behavioral	Severe behavioral
	COMPORTMENT	behavior	comportment, empathy,	in behavior.	changes, affecting	changes, making
	AND		appropriateness of actions.		interpersonal	interpersonal
	PERSONALITY <sup>2</sup>				relationships and	interactions all
					interactions in a	unidirectional.
	•				significant manner.	
<u>10</u> .	LANGUAGE <sup>3</sup>	Normal speech, normal comprehension.	Minimal but noticeable word finding, minimal non-fluency. Comprehension normal in ordinary conversation.	Mild word finding problems event frequently, but does not significantly degrade broken speech. Or mild comprehension difficulties.	Moderate word-finding problems, interferes significantly with communication or moderate nonfluency or moderate comprehension difficulty in ordinary conversation.	Severe deficits in word finding, expressive speech, comprehension making communication virtually nil.

<sup>&</sup>lt;sup>1</sup> Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurology* 43(11):2412-4, 1993. Copyright© Lippincott, Williams & Wilkins. Reproduced by permission.

<sup>&</sup>lt;sup>2</sup> Excerpted from the Frontotemporal Dementia Multicenter Instrument & MR Study (Mayo Clinic, UCSF, UCLA, UW).

<sup>&</sup>lt;sup>3</sup> Excerpted from the PPA-CRD: A modification of the CDR for assessing dementia severity in patients with Primary Progressive Aphasia (Johnson N, Weintraub S, Mesulam MM), 2002.

NACC UDS Coding Guidebook for IVP (version 2.0, February 2008)

## Form B5: BEHAVIORAL ASSESSMENT – NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE (NPI-Q<sup>1</sup>)

The form is to be completed by the clinician or other trained health professional per informant interview. ADC personnel must be certified as an NPI-Q interviewer through the online training system developed by the University of California Los Angeles and NACC. The NPI-Q Interviewer Certification system may be accessed through the NACC website at <a href="https://www.alz.washington.edu/npiq/signin.html">https://www.alz.washington.edu/npiq/signin.html</a>. The procedures established in the training system must be followed to complete this form.

Please ask the following questions based upon <u>changes</u>. Indicate "yes" only if the symptom has been present in the <u>past month</u>; otherwise, indicate "no". For each item marked "yes", rate the SEVERITY of the symptom (how it affects the patient): 1 = Mild (noticeable, but not a significant change) 2 = Moderate (significant, but not a dramatic change) 3 = Severe (very marked or prominent; a dramatic change)

1. NPI informant: 1 Spouse 2 Child 3 Other (specify):	_	Yes	No				Severity	
2. DELUSIONS: Does the patient believe that others are stealing from him or her, or planning to harm him or her in some way?	2a.	□ 1			2b.	□ 1	□ 2	□ 3
3. HALLUCINATIONS: Does the patient act as if he or she hears voices? Does he or she talk to people who are not there?	3a.	□ 1	□ 0		3b.	□ 1	□ 2	□ 3
4. AGITATION OR AGGRESSION: Is the patient stubborn and resistive to help from others?	4a.	□ 1			4b.	□ 1	$\Box 2$	□ 3
5. DEPRESSION OR DYSPHORIA: Does the patient act as if he or she is sad or in low spirits? Does he or she cry?	5a.	□ 1	□ 0		5b.	□ 1	□ 2	□ 3
6. ANXIETY: Does the patient become upset when separated from you? Does he or she have any other signs of nervousness, such as shortness of breath, sighing, being unable to relax, or feeling excessively tense?	ба.	□ 1			6b.	□ 1	□ 2	□ 3
7. ELATION OR EUPHORIA: Does the patient appear to feel too good or act excessively happy?	7a.	□ 1	□ 0		7b.	□ 1	$\Box 2$	□ 3
<ol> <li>APATHY OR INDIFFERENCE: Does the patient seem less interested in his or her usual activities and in the activities and plans of others?</li> </ol>	8a.	□ 1			8b.	□ 1	□ 2	□ 3
9. DISINHIBITION: Does the patient seem to act impulsively? For example, does the patient talk to strangers as if h or she knows them, or does the patient say things that may hurt people's feelings?	е 9а.	□ 1			9b.	□ 1	□ 2	□ 3
10. IRRITABILITY OR LABILITY: Is the patient impatient or cranky? Does he or she have difficulty coping with delays or waiting for planned activities?	10a.	□ 1		1	0b.	□ 1	□ 2	□ 3
11. MOTOR DISTURBANCE: Does the patient engage in repetitive activities, such as pacing around the house, handling buttons, wrapping string, or doing other things repeatedly?	11a.	□ 1	□ 0	1	1b.	□ 1	□ 2	□ 3
12. NIGHTTIME BEHAVIORS: Does the patient awaken you during the night, rise too early in the morning, or take excessive naps during the day?	12a.	□ 1		1	2b.	□ 1	□ 2	□ 3
13. APPETITE AND EATING: Has the patient lost or gained weight, or had a change in the food he or she likes?	13a.	□ 1	□ 0	1	3b.	□ 1	□ 2	□ 3

<sup>&</sup>lt;sup>1</sup> Copyright© Jeffrey L. Cummings, MD. Reproduced by permission.

## Form B6: BEHAVIORAL ASSESSMENT – GERIATRIC DEPRESSION SCALE (GDS<sup>1</sup>)

The form is intended for completion by clinician or other trained health professional as a direct subject interview. The form is <u>not</u> to be administered to the informant. If your Center prefers to administer the entire 30-item GDS, please <u>first</u> administer this 15-item form and score appropriately; then administer the remaining 15 items on a separate non-UDS form.

The Geriatric Depression Scale was developed by Stanford University as a basic screening measure for depression in older adults. Further information is available online at <a href="http://www.stanford.edu/~yesavage/GDS.html">http://www.stanford.edu/~yesavage/GDS.html</a>.

□ Check this box and enter "88" below for the Total GDS Score <u>if and only</u> if the subject:
 1) does not attempt the GDS, or 2) answers fewer than twelve questions.

Instruct the subject: "In the next part of this interview, I will ask you questions about your feelings. Some of the questions I will ask you may not apply, and some may make you feel uncomfortable. For each question, please answer "yes" or "no", depending on how you have been feeling **in the past week, including today**."

		Yes	No
1.	Are you basically satisfied with your life?	0	1
2.	Have you dropped many of your activities and interests?	1	0
3.	Do you feel that your life is empty?	1	0
4.	Do you often get bored?	1	0
5.	Are you in good spirits most of the time?	0	1
6.	Are you afraid that something bad is going to happen to you?	1	0
7.	Do you feel happy most of the time?	0	1
8.	Do you often feel helpless?	1	0
9.	Do you prefer to stay at home, rather than going out and doing new things?	1	0
10.	Do you feel you have more problems with memory than most?	1	0
11.	Do you think it is wonderful to be alive now?	0	1
12.	Do you feel pretty worthless the way you are now?	1	0
13.	Do you feel full of energy?	0	1
14.	Do you feel that your situation is hopeless?	1	0
15.	Do you think that most people are better off than you are?	1	0
16.	Sum all circled answers for a Total GDS Score(maximum score = 15)(did not complete = 88)		
	Calculate the sum of values for all circled answers and enter the total score in the calculation may include a maximum of 3 missing items, and the final sum must be number of missing items (see instructions below for prorating scores). If more that	prorated fo	r the

however, the test must be considered incomplete and the Total GDS Score coded "88". <u>Prorating scores (what to do if the subject misses up to 3 items)</u>: If up to 3 of the 15 items are missing, add the total score on the completed items <u>plus an estimated score for the missing items</u> to get a total score. The estimated score for missing items is calculated as:

#### Total score of completed items/(# of completed items) \* (# of missing items)

You may get a fractional answer that requires rounding. For example, if the subject got a score of 5 for 12 completed items, then the estimated total score is 5 + [(5/12) \* 3] = 6.25. Since the decimal portion of this value is <0.50, the total GDS score is 6.

<sup>&</sup>lt;sup>1</sup>Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clinical Gerontology: A Guide to Assessment and Intervention 165-173, NY: The Haworth Press, 1986. Reproduced by permission of the publisher.

## Form B7: FUNCTIONAL ASSESSMENT – FUNCTIONAL ASSESSMENT QUESTIONNAIRE (FAQ<sup>1</sup>)

NOTE: This form is to be completed by the clinician or other trained health professional, based on information provided by informant. For additional clarification and examples, see UDS Coding Guidebook for Initial Visit Packet, Form B7. Indicate the level of performance for each activity by circling the <u>one</u> appropriate response.

The form is intended for completion by clinician or other trained health professional per informant interview. The intent of the FAQ is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. Circle the most accurate response, based on the informant's assessment.

In the past four weeks, did the subject have any difficulty or need help with:	Not applicable (e.g., never did)	Normal	Has difficulty, but does by self	Requires assistance	Dependent
1. Writing checks, paying bills, or balancing a checkbook.	8	0	1	2	3
2. Assembling tax records, business affairs, or other papers.	8	0	1	2	3
3. Shopping alone for clothes, household necessities, or groceries.	8	0	1	2	3
4. Playing a game of skill such as bridge or chess, working on a hobby.	8	0	1	2	3
5. Heating water, making a cup of coffee, turning off the stove.	8	0	1	2	3
6. Preparing a balanced meal.	8	0	1	2	3
7. Keeping track of current events.	8	0	1	2	3
8. Paying attention to and understanding a TV program, book, or magazine.	8	0	1	2	3
9. Remembering appointments, family occasions, holidays, medications.	8	0	1	2	3
10. Traveling out of the neighborhood, driving, or arranging to take public transportation.	8	0	1	2	3

Self-explanatory. If the informant indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject <u>could</u> still do the task. This will help tease out the relevant cognitive impairment.

<sup>&</sup>lt;sup>1</sup>Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities of older adults in the community. *J Gerontol* 37:323-9, 1982. Copyright<sup>©</sup> The Gerontological Society of America. Reproduced by permission of the publisher.

## Form B8: EVALUATION – PHYSICAL/NEUROLOGICAL EXAM FINDINGS

The purpose of this form is to describe the overall physical/neurological exam findings (non-cognitive, non-behavior based). The form should be completed by the clinician, based on review of all examinations and findings for the current visit.

PH	YSICAL/NEUROLOGICAL EXAM FINDINGS	Yes	No	Unknown
1.	Are all findings unremarkable (normal or normal for age)?	□ 1	$\Box 0$	□ 9
2.	Are focal deficits present indicative of central nervous system disorder?	□ 1		□ 9
3.	Is gait disorder present indicative of central nervous system disorder?	□ 1		□ 9
4.	Are there eye movement abnormalities present indicative of central nervous system disorder?	□ 1		□ 9
	Check number 9 only if there is no information ava	ailable to the	clinician.	

## Form B9: CLINICIAN JUDGMENT OF SYMPTOMS

The purpose of this form is to provide clinical determination of the onset of symptoms. The form should be completed by the clinician, and conclusions should be based on information obtained through subject, informant, medical records and/or observation. Neuropsychological test battery (except for the MMSE) and imaging results should <u>not</u> be used to determine answers for this form, but should be used to make the official clinical diagnosis on Form D1.

MEMO	RY COMPLAINT/AGE OF ONSET:	Yes	No			
Relative	to previously attained abilities:					
1.	Does the subject report a decline in memory?	$\Box$ 1	$\Box 0$			
	Decline refers to cognitive changes in the subject's usual or customary m the subject reports a current (i.e., recent) decline in memory function. This and not behavior, motor, or other non-memory symptoms.					
2.	Does the informant report a decline in subject's memory?	$\Box$ 1				
	Decline refers to cognitive changes in the subject's usual or customary me the informant reports a current (i.e., recent) decline in the subject's memory to memory only and not behavior, motor, or other non-memory symptoms this question blank.	ory function.	This question refer			
	Does the clinician believe there has been a current meaningful decline in the subject's memory, non-memory cognitive abilities, behavior, or ability to manage her/his affairs, or have there been motor/movement changes?	□ 1	□ 0 (If no, end form here)			
	Cognitive decline refers to changes in the subject's usual or customary m	nemory <mark>or no</mark>	on-memory cognitiv			
	abilities reported or observed at the current visit.					
	abilities reported or observed at the current visit. Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels current visit.					
	Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels	reported or	observed at the			
	Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels current visit. Decline or changes in motor/movement refers to meaningful decline from customary level (for example, as evidenced by gait disorder, falls, tremor	reported or the subject and slowne	observed at the 's usual or ss) reported or ificant) in the			
	Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels current visit. Decline or changes in motor/movement refers to meaningful decline from customary level (for example, as evidenced by gait disorder, falls, tremor observed at the current visit. If the clinician is certain that there has been no meaningful decline (i.e., or subject's memory, non-memory cognitive abilities, behavior, or ability to r	reported or the subject and slowne linically sign nanage affa	observed at the 's usual or ss) reported or ificant) in the irs, check "no" and			
	Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels current visit. Decline or changes in motor/movement refers to meaningful decline from customary level (for example, as evidenced by gait disorder, falls, tremor observed at the current visit. If the clinician is certain that there has been no meaningful decline (i.e., or subject's memory, non-memory cognitive abilities, behavior, or ability to r do not complete the remainder of this form. If the clinician is certain that there has been a meaningful decline, check	reported or the subject and slowne linically sign nanage affa "yes" and co	observed at the 's usual or ss) reported or ificant) in the irs, check "no" and ontinue to question			
3b.	<ul> <li>Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels current visit.</li> <li>Decline or changes in motor/movement refers to meaningful decline from customary level (for example, as evidenced by gait disorder, falls, tremor observed at the current visit.</li> <li>If the clinician is certain that there has been no meaningful decline (i.e., or subject's memory, non-memory cognitive abilities, behavior, or ability to r do not complete the remainder of this form.</li> <li>If the clinician is certain that there has been a meaningful decline, check 3b.</li> <li>If the clinician is uncertain whether there has been a meaningful decline, decline,</li> </ul>	reported or the subject and slowne clinically sign manage affa "yes" and co s/he should	observed at the 's usual or ss) reported or ificant) in the irs, check "no" and ontinue to question			
3b.	Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels current visit. Decline or changes in motor/movement refers to meaningful decline from customary level (for example, as evidenced by gait disorder, falls, tremor observed at the current visit. If the clinician is certain that there has been no meaningful decline (i.e., or subject's memory, non-memory cognitive abilities, behavior, or ability to r do not complete the remainder of this form. If the clinician is certain that there has been a meaningful decline, check 3b. If the clinician is uncertain whether there has been a meaningful decline, check 3b.	reported or the subject and slowne clinically sign manage affa "yes" and co s/he should	observed at the 's usual or ss) reported or ificant) in the irs, check "no" and ontinue to question <u>first complete</u> (999=Unknown) (888= N/A)			
3b.	Decline or changes in behavior and ability to manage her/his affairs refer from the subject's usual or customary behavior or functional ability levels current visit. Decline or changes in motor/movement refers to meaningful decline from customary level (for example, as evidenced by gait disorder, falls, tremor observed at the current visit. If the clinician is certain that there has been no meaningful decline (i.e., or subject's memory, non-memory cognitive abilities, behavior, or ability to r do not complete the remainder of this form. If the clinician is certain that there has been a meaningful decline, check 3b. If the clinician is uncertain whether there has been a meaningful decline, check 3b. At what age did the cognitive decline begin (based upon the clinician's assessment)? Cognitive decline refers to changes in the subject's usual or customary not subject's usual or customary and the subject's usual or customary not subject's usual or customary and the subject's usual or customary not subject's usual or customary not subject's usual or customary and the subject's usual or customary not subject's usual or customary not subject's usual or customary and the subject's usual or customary not subject's usual or customar	reported or the subject and slowne clinically sign manage affa "yes" and co s/he should 	observed at the 's usual or ss) reported or ificant) in the irs, check "no" and ontinue to question <u>first complete</u> (999=Unknown) (888= N/A) on-memory cognitiv enter "999". Any			
CC	GNITIVE SYMPTOMS:		Yes	No	Unknown	
----	--	--	------------	------------------	----------	--
4.	Indicate whether the subject currently is impaired mean previously attained abilities, in the following cognitive fluctuating cognition:					
	a. <b>Memory</b> (For example, does s/he forget conversating questions and/or statements; misplace more than us s/he knows well?)	□ 1		□9		
	b. <b>Judgment and problem-solving</b> (For example, do handling money (tips); paying bills; shopping; prepappliances; handling medications; driving?)	□ 1		□9		
	c. <b>Language</b> (For example, does s/he have hesitant sp words; use inappropriate words without self-correct		□ 1	$\Box 0$	□9	
	d. <b>Visuospatial function</b> (For example, does s/he have visual stimuli; finding her/his way around.)	ve difficulty interpreting	□ 1	$\Box 0$	□9	
	e. Attention/concentration (For example, does the s span or ability to concentrate? Is s/he easily distract		□ 1	$\Box 0$	□9	
	f. Fluctuating cognition (Does s/he have pronounced alertness, noticeably over hours or days? For exam- into space or lapses, or times when her/his ideas has	ple, long periods of staring	□ 1	$\Box 0$	□9	
	g. Other (If yes, then specify):		□ 1	$\Box 0$	□9	
	Self-explanatory. Check number 9 only if the answ from the subject, informant, medical records, and If the subject exhibits a meaningful decline in any under "Other" and check number 1 (yes).	/or observation.	·		_	
5.		Memory	$\Box 6 O$	Other (specify):		
		Judgment and problem solving	□7 F	Fluctuating cog	nition	
		Language	🗆 88 N	√/A		
		Visuospatial function Attention/concentration	□99 U	Jnknown		
	This question refers to the onset of the cognitive change (i.e., when change in cognition was first noticed). If the informant or available information indicates that several symptoms occurred simultaneously, the clinician must ask the informant and/or use her/his best clinical judgment to commit to one of the symptoms as the predominant symptom.					
	If the predominant cognitive symptom first recogn 6 and briefly describe in the space provided.	ized as a decline was other	than thos	e listed, checł	( number	
	Check number 88 if there was no decline in the su	ubject's cognition.				
	Check number 99 only if clinician is unable to asc on available information or observation.	certain the cognitive symptor	n predomi	inant at onset	, based	

6. Mode of onset of cognitive symptoms:

 $\Box$  1 Gradual (> 6 months)

 $\Box$  4 Other (*specify*):

 $\Box$  2 Subacute ( $\leq$  6 months)

 $\Box$  3 Abrupt (*within days*)

□ 88 N/A □ 99 Unknown

This question refers to the onset of the cognitive change (i.e., when change in cognition was first noticed). The clinician should choose the option that most closely resembles the mode of onset of cognitive symptoms for the subject.

If the mode of onset was other than those listed, check number 4 and briefly describe in the space provided.

Check number 88 if there was no decline in the subject's cognition.

Check number 99 only if no information is available to allow the clinician to ascertain the mode of onset.

BF	ЕНА	VIOR SYMPTOMS:	Yes	No	Unknown
7.		dicate whether the subject currently manifests the following behavioral			
		mptoms:			
	<ul> <li>a. Apathy/withdrawal (Has the subject lost interest in or displayed a reduced ability to initiate usual activities and social interaction, such as conversing with family and/or friends?)</li> <li>b. Depression (Has the subject seemed depressed for more than two weeks at a time; e.g., loss of interest or pleasure in nearly all activities; sadness, hopelessness, loss of appetite, fatigue?)</li> </ul>		□ 1	$\Box 0$	□9
			□ 1	$\Box 0$	□9
	c.	Psychosis			
		1) Visual hallucinations	$\Box$ 1	$\Box 0$	□ 9
		a) If yes, are the hallucinations well-formed and detailed?	$\Box 1$	$\Box 0$	□ 9
		Check 'yes' if the hallucinations are formed and detailed (e.g., people	e, animals (	or objects, no	t just
		vague visual images, blurs, lines or colors).			
		2) Auditory hallucinations	□ 1	$\Box 0$	□ 9
		3) Abnormal/false/delusional beliefs	$\Box 1$	$\Box 0$	□ 9
	d.	<b>Disinhibition</b> (Does the subject use inappropriate coarse language or exhibit inappropriate speech or behaviors in public or in the home? Does s/he talk personally to strangers or have disregard for personal hygiene?)	□ 1	$\Box 0$	□9
	e.	<b>Irritability</b> (Does the subject overreact, such as shouting at family members or others?)	$\Box 1$	$\Box 0$	□ 9
	f.	<b>Agitation</b> (Does the subject have trouble sitting still; does s/he shout, hit, and/or kick?)	$\Box$ 1		□ 9
	g.	<b>Personality change</b> (Does the subject exhibit bizarre behavior or behavior uncharacteristic of the subject, such as unusual collecting, suspiciousness [without delusions], unusual dress, or dietary changes? Does the subject fail to take other's feelings into account?)	□ 1		□9
	<mark>h.</mark>	<b>REM sleep behavior disorder</b> (Does the subject appear to act out her/his dreams while sleeping (e.g., punch or flail their arms, shout or scream?)	$\Box 1$	$\Box 0$	□ 9
	<mark>i.</mark>	Other (If yes, then specify):	$\Box$ 1	$\Box 0$	□9
1					

If these symptoms are reported or observed to reflect the subject's condition at this clinical evaluation based upon information gathered from the subject, informant, medical records, and/or observation, then answer "yes" (1); otherwise, answer "no" (0). Check "unknown" (9) only if the answer cannot be determined based upon information gathered from the subject, informant, medical records, and/or observation.

If the subject exhibits a meaningful decline in any behavior other than those listed, briefly describe under "Other" and check number 1 (yes).

8.	Indicate the <u>predominant</u> symptom which was first recognized as a decline in the subject's behavioral symptoms:	$\Box 1$ $\Box 2$ $\Box 3$ $\Box 4$ $\Box 5$	Apathy/withdrawal Depression Psychosis Disinhibition	□ 7 □ 8 □ 9 □ 88	Personalit Other ( <i>spe</i> <u>REM slee</u> N/A	ecify):	r disorder
		$\Box 5$ $\Box 6$	Irritability Agitation	□ 99	Unknowr	1	
	This question refers to the subject's sym information indicates that several sympto and/or use her/his best clinical judgment If the predominant behavioral symptom f	ptoms a oms occ to com	at onset of behavior chang curred simultaneously, the mit to one of the sympton	clinicians as th	an must as ne predom	sk the info inant sym	ormant nptom.
	number 8 and briefly describe in the spa					, -	
	Check number 88 if there was no decline	e in the	subject's behavior.				
	Check number 99 only if clinician is unal on available information or observation.	ole to as	scertain the behavioral sy	mptom	predomin	ant at ons	set, based
9.	Mode of onset of behavioral symptoms:	$\Box 1$ $\Box 2$ $\Box 3$	Gradual (> 6 months) Subacute ( $\leq 6$ months) Abrupt (within days)	□ 4 □ 88 □ 99	Other ( <i>spe</i>  N/A Unknowr		
	The clinician should choose the option the symptoms for the subject. If the mode of onset was other than those	e listed	, check number 4 and brid				
	Check number 88 if there was no decline Check number 99 only if no information			o asce	rtain the m	node of o	nset.
	DTOR SYMPTOMS:			Y	es	No	Unknown
10.	Indicate whether the subject currently has the						
	a. <b>Gait disorder</b> (Has the subject's walking arthritis or an injury? Is s/he unsteady, or have little or no arm-swing, or drag a foo	does s/h			1		□ 9
	b. Falls (Does the subject fall more than us	ual?)			] 1	$\Box 0$	□ 9
	c. <b>Tremor</b> (Has the subject had rhythmic st arms, legs, head, mouth, or tongue?)	-			1	$\Box 0$	□ 9
	d. <b>Slowness</b> (Has the subject noticeably slowed down in walking or moving or handwriting, other than due to an injury or illness? Has her/his facial expression changed, or become more "wooden" or masked and unexpressive?)				1	□ 0	□ 9
	If these symptoms are reported or obser upon information gathered from the subj "yes" (1); otherwise, answer "no" (0). Ch upon information gathered from the subj	<mark>ect, info</mark> eck "unl	rmant, medical records, a known" (9) only if the answ	and/or o wer car	<mark>bservatio</mark> nnot be de	<mark>n, then ar</mark> termined	nswer

11.	Indicate the predominant symptom which	$\Box 1$	Gait disorder	□ 4	Slowness				
	was first recognized as a decline in the subject's motor symptoms:	$\Box 2$	Falls		N/A				
	subject's motor symptoms.	□ 3	Tremor	□ 99	Unknown				
	This question refers to the subject's symptoms at onset of decline in motor function. If the informant or available information indicates that several symptoms occurred simultaneously, the clinician must ask the informant and/or use her/his best clinical judgment to commit to one of the symptoms as the predominant symptom.								
	Check number 99 only if clinician is unable to ascertain the motor symptom predominant at onset, based on available information or observation.								
12.	Mode of onset of motor symptoms:	$\Box$ 1 $\Box$ 2	Gradual (> $6 \text{ months}$ ) Subacute ( $\leq 6 \text{ months}$ )	□ 4	Other ( <i>specify</i> ):				
		$\square 3$	Abrupt ( <i>within days</i> )		N/A				
		_	· · · · · · · · · · · · · · · · · · ·	□ 99	Unknown				
	Check the option that most closely resem	bles th	e mode of onset of motor sy	/mptom	s for the subject.				
	If the mode of onset was other than those	e listed	, check number 4 and briefly	describ	be in the space provided.				
	Check number 88 if there was no decline	in the	subject's behavior.						
	Check number 99 only if no information is	s availa	ble to allow the clinician to a	ascertaii	n the mode of onset.				
	a. If there were changes in motor function,	were the	ese suggestive of	<mark>□ 1</mark>	Yes				
	parkinsonism?			0 🗆	No				
				<mark>□ 88</mark>	N/A				
	Self-explanatory.								
13.	Course of overall cognitive/behavioral/	$\Box$ 1	Gradually progressive	□ 4	Fluctuating				
	motor syndrome:	$\Box 2$	Stepwise	$\Box$ 5	Improved				
		□ 3	Static	□ 9	Unknown				
	Check the appropriate number to indicate the course of the illness. Fluctuating court								
	Check number 9 only if no information is available to allow the clinician to describe the overall course of the syndrome.								
14.									
1 ·	Indicate the predominant domain which was	□ 1	Cognition	□ 3	Motor function				
	Indicate the <u>predominant</u> domain which was first recognized as changed in the subject:	$\Box 1$ $\Box 2$	Cognition Behavior	□ 3 □ 9	Motor function Unknown				
		□ 2 e which	Behavior domain appears to be the f	□ 9 irst to ha	Unknown ave changed in the				

## Form C1: MMSE AND NEUROPSYCHOLOGICAL BATTERY

This form should be completed by ADC or clinic staff, based on subject response. If the subject cannot complete a particular exam, refer to the appropriate key for coding entry. Worksheets and instructions referenced below and included in the "Instructions for Neuropsychological Tests (Form C1)" are based on those provided in the Multiplex Family Study Procedures Manual (created by Columbia University for the Alzheimer's Disease Genetics Initiative) and adapted by the Alzheimer's Disease Neuroimaging Initiative.

NOTE: Due to copyright restrictions, the actual test forms and relevant instructions are only available to researchers affiliated with NIA-approved Alzheimer's Disease Centers. Contact information for the publishers is provided for other researchers.

The MMSE can be administered by the clinician during the neurological evaluation or by the neuropsychometrist/clinic staff as part of the neuropsychological test battery. In either case, the MMSE must be administered exactly as shown in the "Instructions for Neuropsychological Tests (Form C1)".

KEY:		If the subject cannot complete any of the following exams, please use the following codes for the test scores (except the Trail Making Test): 95 = Physical problem 96 = Cognitive/behavior problem 98 = Verbal refusal			
1.	Mi	ni Mental State Examination			
	1a.	The administration of the MMSE was: $\Box$ 1 In ADC/ $\Box$ 2 In home $\Box$ 3 In person–other clinic			
		1) Language of MMSE administration: 1 English 2 Spanish 3 Other (specify):			
		Indicate the primary language used when administering the MMSE test.			
	1b.	Orientation subscale scores:			
		1) Time: (0–5) see Key			
		2) Place: (0–5) <i>see Key</i>			
	1c.	Intersecting pentagon subscale score: (0–1) see Key			
	<mark>1d.</mark>	Total MMSE score (using D-L-R-O-W)(0-30) see Key			
	The Mini-Mental State Examination is a screening scale that evaluates orientation orientation to time, registration (immediate repetition of three words), attention a concentration (spelling D-L-R-O-W), recall (recalling the previously repeated the language (naming, repetition, reading, writing, comprehension), and visual const two intersecting pentagons). The MMSE is scored as the number of correctly criteres, with lower scores indicative of poorer performance and greater cognitive Review the "Instructions for Neuropsychological Tests (Form C1)" and complet worksheet. Compute the scores for Orientation to Time, Orientation to Place, Ir Pentagon Subscale Score and Total MMSE Score, and enter those numbers in				
		provided on NACC UDS Form C1. The form and instructions are reproduced by special permission of the publisher, Psychological Assessment Resources, Inc., 16204 North Florida Avenue, Lutz, FL 33549, from the Mini Mental LLC, Inc. Published 2001 by Psychological Assessment Resources, Inc. Further reproduction is prohibited without permission of PAR, Inc.			

It is intended that the tests be administered in the order in which they appear **even if they were previously administered at a recent clinic screening**. This is necessary in order to standardize among Centers the delay intervals for testing memory, and also to eliminate any differences due to the order of test administration. It is therefore suggested that the UDS be administered in its entirety either before or after the administration of other tests commonly used by the Center.

2.		e remainder of the battery (below) was	1 In ADC/ clinic	$\Box$ 2 In home	$\Box$ 3 In person–other		
	Self	f-explanatory.					
	2a.	Language of test administration:	□ 1 English	□ 2 Spanish	□ 3 Other (specify):		
		Indicate the primary language used when	administering t	he remainder of	the tests.		
3.	Log	zical Memory IA – Immediate					
	3a.	If this test has been administered to the subject within the past 3 months, specify the date previously administered:	t //	<mark>(88/88/88</mark>	388 = N/A)		
	This test is a measure of memory (declarative/episodic) in which a brief story is read to the subject, who is then asked to retell it from memory immediately. The primary measure of performance is the number of story units recalled. Alternate paragraphs for the Logical Memory stories are not available, so as not to introduce more variability.						
		Enter the date of administration if the subju- prior to the current visit.	ect has comple	eted this test with	in the three months		
		Wechsler Memory Scale® – Revised. Cop Assessment, Inc. Reproduced with permis and "WMS" are trademarks of Harcourt As America and other jurisdictions.	sion. All rights	reserved. "Wech	nsler Memory Scale"		
		1) Total score from the previous test admini	istration:		(0–25; 88 = <i>N</i> / <i>A</i> )		
		If the test was administered in the pashas not been administered within the			e here. If the test		
	<mark>3b.</mark>	Total number of story units recalled from this administration:	current test		(0–25) see Key		
		Review the "Instructions for Neuropsychol and enter the total score here.	ogical Tests (F	orm C1)", compl	ete the worksheet,		
4.	Digi	it Span Forward					
	4a.	Total number of trials correct prior to two cons same digit length:	secutive errors a	t the	(0–12) <i>see Key</i>		
	4b.	Digit span forward length:			(0–8) see Key		
		This is a widely used test of working memory number sequences of increasing length ar length is the length of the highest digit seq	nd asked to rep	eat them. The di	igit span forward		
		Review the "Instructions for Neuropsychol and enter here the number of total correct					
		Wechsler Memory Scale® – Revised. Cop Assessment, Inc. Reproduced with permis and "WMS" are trademarks of Harcourt As America and other jurisdictions.	sion. All rights	reserved. "Wech	nsler Memory Scale"		

5.	Digi	t Span Backward
0.	0	Total number of trials correct prior to two consecutive errors at the
		same digit length: $(0-12)$ see Key
	5b.	Digit span backward length:   (0-7) see Key
		This is a widely used measure of working memory (or attention) in which the subject is read number sequences of increasing length and then asked to repeat each sequence backward. The primary measure of performance is the number of digit sequences correctly reversed. The digit span backward length is the length of the highest digit sequence the subject is able to reverse.
		Review the "Instructions for Neuropsychological Tests (Form C1)", complete the worksheet, and enter here the total number of correct trials and the digit span backward length.
		<i>Wechsler Memory Scale</i> ® – <i>Revised</i> . Copyright© 1945, renewed 1974, 1987 by Harcourt Assessment, Inc. Reproduced with permission. All rights reserved. <i>"Wechsler Memory Scale"</i> and <i>"WMS"</i> are trademarks of Harcourt Assessment, Inc., registered in the United States of America and other jurisdictions.
6.	Cat	egory Fluency
	6а.	Animals – Total number of animals named in 60 seconds: (0–77) see Key
	6b.	Vegetables – Total number of vegetables named in 60 seconds: (0–77) see Key
		This is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category, and the number of unique
		exemplars named is scored.
		exemplars named is scored. Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.
KE,	Y 2: If	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two
		Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.         Indexessary, use the following codes for the Trail Making Test only:         995 = Physical problem       997 = Other problem         996 = Cognitive/behavior problem       998 = Verbal refusal
КЕ` 7.	Trai	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.
	Trai	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.         Indexessary, use the following codes for the Trail Making Test only:         995 = Physical problem       997 = Other problem         996 = Cognitive/behavior problem       998 = Verbal refusal
	Trai	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.
	Trai	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.Increase of the state of the state of the state of the score for each test here.Increase of the state of the state of the state of the score for each test here.Increase of the score for the score for each test here.Increase of the score for each test here.Increase of the score for each test here.Increase of the score for the score for the score for each test here.Increase of the score for the score for the score for each test here.Increase of the score for the score for the score for each test here.Increase of the score for the score for the score for the score for each test here.Increase of the score for the scor
	Trai	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.         Inccessary, use the following codes for the Trail Making Test only:         995 = Physical problem       997 = Other problem         996 = Cognitive/behavior problem       998 = Verbal refusal         Il Making Test       Part A-Total number of seconds to complete         (if not finished by 150 seconds, enter 150):       ——— (0–150) see Key 2         1) Number of commission errors       (0–40; 88 = N/A)
	<b>Tra</b> i 7a.	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.         Image: Second State Structure       995 = Physical problem (997 = Other problem 998 = Verbal refusal)         Image: Second State Structure       997 = Other problem (0-150) see Key 2         Image: Second State Structure       998 = Verbal refusal)         Image: Second State Structure       99
	<b>Tra</b> i 7a.	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.         Image: Second state of the second state of t
	<b>Tra</b> i 7a.	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.         Image: Second state of the second state of t
	<b>Tra</b> i 7a.	Review the "Instructions for Neuropsychological Tests (Form C1)", complete the two worksheets provided, and enter the appropriate score for each test here.         Image: Provide of the trail Making Test only:         995 = Physical problem       997 = Other problem         996 = Cognitive/behavior problem       997 = Other problem         996 = Cognitive/behavior problem       998 = Verbal refusal         Il Making Test

8.	WA	IS-R Digit Symbol						
	8a.	Total number of items correctly completed in 90 seconds:	(0–93) see Key					
		This subtest of the WAIS-R engages multiple cognitive abilities, including psychomotor speed, complex scanning, visual tracking, and immediate m						
		Review the "Instructions for Neuropsychological Tests (Form C1)", complete the worksheet, and enter the appropriate score here.						
		Wechsler Adult Intelligence Scale® – Revised. Copyright© 1981, 1955 by Harcourt Assessment, Inc. Reproduced with permission. All rights reserved. <i>"Wechsler Adult Intelligence Scale"</i> and <i>"WAIS"</i> are trademarks of Harcourt Assessment, Inc., registered in the United States of America and other jurisdictions.						
9.	Log	cal Memory IIA – Delayed						
	9a.	Total number of story units recalled:	(0–25) see Key					
	9b.	Time elapsed since Logical Memory IA – Immediate:	(0-85  minutes) $(88 = N/A)$ $(99 = Unknown)$					
		This is a measure of delayed recall (episodic memory) of the story read to the beginning of the testing session.	the participant at					
		Review the "Instructions for Neuropsychological Tests (Form C1)", complete the worksheet, and enter here the total score and the number of minutes elapsed following the administration of <i>Logical Memory IA-Immediate</i> . (Note: Aim for a 20-minute delay; if 20 minutes have not elapsed, do <u>not</u> add other tests to fill the interval. Administer <i>Logical Memory IIA – Delayed</i> and enter the actual time that elapsed.)						
		If Logical Memory IIA - Delayed was not attempted or not completed, ent	er "88" for item 9b.					
		Enter "99" (Unknown) if the time elapsed was not recorded or improperly	recorded.					
		Wechsler Memory Scale® – Revised. Copyright© 1945, renewed 1974, 1 Assessment, Inc. Reproduced with permission. All rights reserved. "Wech Scale" and "WMS" are trademarks of Harcourt Assessment, Inc., registere States of America and other jurisdictions.	sler Memory					
10.	Bost	on Naming Test (30 Odd-numbered items)						
	10a.	Total score:	(0–30) see Key					
		The Boston Naming Test is a measure of the ability to orally label (name) objects. This test is sensitive to aphasia and also to object recognition defined and also to object						
		Review the "Instructions for Neuropsychological Tests (Form C1)", complete and enter the total score here. (You may elect to administer all 60 items, I a supplemental page 2 containing the even-numbered items and administ completing the odd-numbered test. Score only the 30 <u>odd-numbered</u> item	out you must create ter those <u>after</u>					
		Boston Naming Test, second edition. Kaplan E, Goodglass H, Weintraub Lea and Febiger; 1983. Adapted by special permission of the publisher, F Shoal Creek Blvd., Austin TX 78757-6897 (800-897-3202; www.proedinc. Copyright© 2001.	RO-ED Inc., 8700					

11. Overal	ll Appraisal						
ne th	ased on the UDS europsychological examination, e subject's cognitive status is eemed:	$\Box 2$	Better than normal for age Normal for age One or two test scores abnormal		Three or more scores are abnormal or lower than expected Clinician unable to render opinion		
fru ra ba sc ec Ba	he interpretation of neuropsych om dementia that can influence acial/ethnic variables, and the su cluded to obtain the clinical neu ased on the UDS neuropsychol cores obtained from unimpaired ducation. These tables provide ased on the examination, the cl ollowing: ) Better than normal for age: n above what is considered av used clinical norms;	e test ubjec urops ogica I UDS rough linicia nost L	scores (e.g., prior cognitive t's level of cooperation and ychologist's opinion of the I tests. The NACC website S subjects for each test, se n guidelines that can be us n is asked to rate the cogr	e abili subje provi parate ed to nitive s	ty, education, vation). This item is ct's performance, ides tables of mean ed by gender, age, and aid clinical judgment. status as one of the pres are at a level		
2)	<ul> <li>Normal for age: most UDS n considered the average rang</li> </ul>			all at l	east in what is		
<ol> <li>One or two test scores abnormal: most UDS neuropsychological test scores or better but one or two are distinctly abnormal;</li> </ol>							
4)	neuropsychological test scor	are abnormal or lower than expected: three or more UDS st scores are in the abnormal range for age and education OR in lously very high functioning, the scores are beneath expectation, normal;					
0)	) Clinician is unable to render	an op	pinion based on exam and	test r	esults.		

## Form D1: CLINICIAN DIAGNOSIS - COGNITIVE STATUS AND DEMENTIA

The purpose of this form is to record a diagnosis of the subject's current status relative to cognition and dementia. The form should be completed by the clinician, based on a review of all available information.



<sup>&</sup>lt;sup>1</sup> Arch Neurol, 2005. 62;1160-63, Figure 1. Reproduced by permission of the publisher. Copyright© 2005. American Medical Association. All rights reserved.

4.	4. If the subject does not have normal cognition and is not clinically demented, indicate the type of cognitive impairment (choose only <u>one</u> impairment from items 4a thru 4e as being "present"; mark <u>all others</u> "absent") and then designate the suspected underlying cause(s) of the impairment by completing items 5–30:						
	(NOTE: Although items 5–30 were developed for individuals with clinical dementia rather than MCI, for the type of cognitive impairment indicated below in 4a–4e, please designate the suspected cause(s) of the impairment in all cases by completing items 5–30.)						
		Present	Absent				
	4a. Amnestic MCI – memory impairment only	□ 1					
	If memory is impaired and memo	ory is the only	$\gamma$ cognitive domain impaired, mark 4a as "present".				

(Note: Only <u>one</u> of items 4a–4e may be marked "present"; <u>all others</u> must be marked "absent".)

		Present	Absent	Domains	Yes	No		
4b.	Amnestic MCI – memory	$\Box 1$	$\Box 0$	1) Language	$\Box 1$	$\Box 0$		
	impairment plus one or more other domains ( <i>if present, check one or</i> <i>more domain boxes "yes" and</i>			2) Attention	$\Box 1$	$\Box 0$		
				3) Executive function	$\Box 1$	$\Box 0$		
	check all other domain boxes "no")			4) Visuospatial	$\Box$ 1	$\Box 0$		
	If memory is impaired, but is <u>not</u> the mark on the list at right the other co your examination and/or neuropsyc	gnitive do	omain(s) w					
4c.	Non-amnestic MCI – single domain	□ 1	$\Box 0$	1) Language	□ 1	$\Box 0$		
	( <i>if present, check only <u>one</u> domain</i> <i>box "yes"; check <u>all other</u> domain</i>			2) Attention	$\Box$ 1	$\Box 0$		
	boxes "no")			3) Executive function	$\Box$ 1	$\Box 0$		
				4) Visuospatial	$\Box$ 1	$\Box 0$		
	s impaired, mark 4c as "pres u judge to be impaired, base							
4d.	Non-amnestic MCI – multiple	$\Box 1$	$\Box 0$	1) Language	$\Box 1$	$\Box 0$		
	domains ( <i>if present, check <u>two</u> or</i> <i>more domain boxes "yes" and</i>			2) Attention	$\Box 1$	$\Box 0$		
	check all other domain boxes "no")			3) Executive function	$\Box 1$	$\Box 0$		
				4) Visuospatial	$\Box 1$	$\Box 0$		
	If memory is <u>not</u> impaired, but <u>more than one</u> other cognitive domain is impaired, mark 4d as "present" and mark on the list at right each of those domains which you judge to be impaired, based on your examination and/or neuropsychological tests.)							
4e.	Impaired, not MCI	□ 1	$\Box 0$					
If you judge the subject to by cognitively impaired, but the subject's presentation, tests, symptoms and clinical evaluation are <u>not consistent with MCI</u> and do not allow you to mark any of the above items (4a–4d) as "present", then mark 4e as "present".								

Please indicate if the following conditions are present or absent. If present, also indicate if the condition is primary or contributing to the observed cognitive impairment (reported in items 3 or 4), based on the clinician's best judgment. Mark only one condition as primary.

				If Present:			·esent·
		Present	Absent			Primary	Contributing
5.	Probable AD (NINCDS/ADRDA) ( <i>if present, skip to item #7</i> )	□ 1	$\Box 0$		5a.	□ 1	□ 2
6.	Possible AD (NINCDS/ADRDA) (if #5 is present, leave this blank)	□ 1	$\Box 0$		ба.	□ 1	□ 2
	<ol> <li>The criteria<sup>1</sup> for the clinical diagnosis of PR4         <ul> <li>dementia established by clinical examinat Dementia Scale, or some similar examinat</li> <li>deficits in two or more areas of cognition;</li> <li>progressive worsening of memory and otf</li> <li>no disturbance of consciousness;</li> <li>onset between ages 40 and 90, most ofte</li> <li>absence of systemic disorders or other br for the progressive deficit in memory and</li> </ul> </li> <li>The diagnosis of PROBABLE Alzheimer's d</li> <li>progressive deterioration of specific cogni (apraxia), and perception (agnosia);</li> <li>impaired activities of daily living and altered family history of similar disorders, particul</li> <li>laboratory results of: normal lumbar puncture as evaluated 1 normal pattern or nonspecific changes evidence of cerebral atrophy on CT wit</li> <li>Other clinical features consistent with the di exclusion of causes of dementia other than</li> <li>plateaus in the course of progression of tf</li> <li>associated symptoms of depression, inso catastrophic verbal, emotional, or physica</li> <li>other neurologic abnormalities in some pa including motor signs such as increased r</li> <li>seizures in advanced disease; and</li> <li>CT normal for age.</li> <li>IV. Features that make the diagnosis of PROB/ include:</li> <li>sudden, apoplectic onset;</li> <li>focal neurologic findings such as hemipar incoordination early in the course of the ill</li> <li>seizures or gait disturbances at the onset</li> </ol>	tion and doc ation, and co ner cognitive an after age cognition. lisease is su itive function ed patterns arly if confir by standard in EEG, su th progressi agnosis of F Alzheimer's ne illness; mnia, incon al outbursts, atients, espe muscle tone ABLE Alzhe	sumented by ponfirmed by i e functions; 65; and s that in and opported by: ns such as la of behavior; med neurop techniques; ch as increa on documer PROBABLE disease, ind tinence, delu sexual dison ecially with n , myoclonus	and batt ise Alusi rde noi s, o al f	e Mini-N uropsyck f themse guage (a nologica d slow-v d by ser zheimer ide: ions, illus ers, and re advar or gait dis e uncerta field defi e of the i	Mental Tes hological t elves could aphasia), r lly; and wave activ ial observa 's disease sions, hall weight los nee diseas sorder. hin or unlik icits, and llness.	ests; d account notor skills ity; and ation. , after ucinations, s; e and

<sup>&</sup>lt;sup>1</sup>McKhann G, Drachman D, Folstin M, Katzman R, Price D, and Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 July, (34) 939-944.

- V. Clinical diagnosis of POSSIBLE Alzheimer's disease:
  - may be made on the basis of the dementia syndrome, in the absence of other neurologic, psychiatric, or systemic disorders sufficient to cause dementia, and in the presence of variations in the onset, in the presentation, or in the clinical course;
  - may be made in the presence of a second systemic or brain disorder sufficient to produce dementia, which is not considered to be *the* cause of the dementia; and
  - should be used in research studies when a single gradually progressive severe cognitive deficit is identified in the absence of other identifiable cause.
- VI. Criteria for diagnosis of DEFINITE Alzheimer's disease are:
  - the clinical criteria for probable Alzheimer's disease and
  - histopathologic evidence obtained from a biopsy or autopsy.
- VII. Classification of Alzheimer's disease for research purposes should specify features that may differentiate subtypes of the disorder, such as:
  - familial occurrence;
  - onset before age of 65;
  - presence of trisomy-21; and
  - coexistence of other relevant conditions such as Parkinson's disease.

	Present	Absent	Prim	If Present: ary Contributing
7. Dementia with Lewy bodies		$\Box 0$	7a. 🗆	
Revised (2005) criteria for the clini	ical diagnosis o	f dementia v	vith Lewy bodi	ies (DLB) <sup>1</sup> :
<ol> <li>Central feature (essential for a diagnosis of p Dementia defined as progressive cognitive d or occupational function. Prominent or persis early stages but is usually evident with progr visuospatial ability may be especially promin</li> </ol>	decline of sufficient stent memory impression. Deficits of	nt magnitude pairment may	not necessaril	y occur in the
<ul> <li>2. Core features (two core features are sufficient</li> <li>Fluctuating cognition with pronounced variations</li> <li>Recurrent visual hallucinations that are type</li> <li>Spontaneous features of parkinsonism.</li> </ul>	ations in attentior	n and alertnes	SS.	ossible DLB):
<ul> <li>3. Suggestive features (If one or more of these diagnosis of probable DLB can be made. In features is sufficient for possible DLB. Proba suggestive features alone):</li> <li>REM sleep behavior disorder.</li> <li>Severe neuroleptic sensitivity.</li> <li>Low dopamine transporter uptake in basal</li> </ul>	the absence of a able DLB should i	ny core featu not be diagno	res, one or moi osed on the bas	re suggestive is of
<ul> <li>4. Supportive features (commonly present but in Repeated falls and syncope.</li> <li>Transient, unexplained loss of consciousnee</li> <li>Severe autonomic dysfunction, e.g., orthos</li> <li>Hallucinations in other modalities.</li> <li>Systematized delusions.</li> <li>Depression.</li> <li>Relative preservation of medial temporal lo</li> <li>Generalized low uptake on SPECT/PET per Abnormal (low uptake) MIBG myocardial secondary on EEG with the second se</li></ul>	not proven to hav ess. static hypotension be structures on erfusion scan with cintigraphy.	ve diagnostic n, urinary inco CT/MRI scar n reduced occ	specificity): ontinence. n. cipital activity.	
<ul> <li>5. A diagnosis of DLB is <i>less likely</i>:</li> <li>In the presence of cerebrovascular disease</li> <li>In the presence of any other physical illnes for the clinical picture.</li> <li>If parkinsonism only appears for the first time</li> </ul>	s or brain disorde	er sufficient to	account in par	
6. <i>Temporal sequence</i> of symptoms: DLB should be diagnosed when dementia of present). The term Parkinson disease deme occurs in the context of well-established Pa appropriate to the clinical situation should b helpful. In research studies in which distinct 1-year rule between the onset of dementia a Adoption of other time periods will simple of other research settings that may include clin phenotypes may be considered collectively synucleinopathy.	occurs before or o entia (PDD) shou arkinson disease. be used and gene tion needs to be i and parkinsonism onfound data poo nicopathologic st r under categories	concurrently Ild be used to In a practice eric terms suc made betwee n DLB contine oling or comp udies and clir s such as LB	with parkinsonis describe deme setting, the ten th as LB diseas on DLB and PD ues to be recon arison between nical trials, both disease or alph	entia that m that is most e are often D, the existing nmended. a studies. In clinical na-
(For more information on the criteria above, http://www.lewybodydementia.org/lbdsympt		e of the Lewy	Body Dementia	a Association a

<sup>&</sup>lt;sup>1</sup> McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and Management of Dementia with Lewy Bodies: Third report of the DLB Consortium, Neurology 2005; 65:1863-72.

					If P	resent:
		Present	Absent		Primary	Contributing
8.	Vascular dementia (NINDS/AIREN Probable) (if present, skip to item #10)	□ 1		8a	. 🗆 1	□ 2
<mark>9.</mark>	Vascular dementia (NINDS/AIREN Possible) (if #8 is present, leave this blank)		<mark>□ 0</mark>	<mark>9a</mark>	. 🗆 1	<mark>□ 2</mark>

This category is for dementia subjects that meet <u>Probable</u> NINDS-AIREN criteria for vascular dementia, which should therefore be designated as the primary etiology of the dementia. For mixed dementias or subjects meeting only <u>Possible</u> NINDS-AIREN criteria for vascular dementia, check number 1 ("present") for Question 24 below and indicate that stroke is contributory to the cognitive impairment.

#### NINDS-AIREN criteria for the diagnosis of vascular dementia<sup>1</sup>:

### I. The criteria for the clinical diagnosis of probable vascular dementia include all of the following:

*Dementia* defined by cognitive decline from a previously higher level of functioning and manifested by impairment of memory and of two or more cognitive domains (orientation, attention, language, visuospatial functions, executive functions, motor control, and praxis), preferable established by clinical examination and documented by neuropsychological testing; deficits should be severe enough to interfere with activities of daily living not due to physical effects of stroke alone.

*Exclusion criteria*: cases with disturbance of consciousness, delirium, psychosis, severe aphasia, or major sensorimotor impairment precluding neuropsychological testing. Also excluded are systemic disorders or other brain diseases (such as AD) that in and of themselves could account for deficits in memory and cognition.

*Cerebrovascular disease*, defined by the presence of focal signs on neurologic examination, such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, hemianopia, and dysarthria consistent with stroke (with or without history of stroke), and evidence of no relevant CVD by brain imaging (CT or MRI) including *multiple large vessel infarcts* or a *single strategically placed infarct* (angular gyrus, thalamus, basal forebrain, or PCA or ACA territories), as well as *multiple basal ganglia* and *white matter lacunes*, or *extensive periventricular white matter lesions*, or combinations thereof.

A relationship between the above two disorders, manifested or inferred by the presence of one or more of the following: (a) onset of dementia within 3 months following a recognized stroke; (b) abrupt deterioration in cognitive functions; or fluctuating, stepwise progression of cognitive deficits.

# II. Clinical features consistent with the diagnosis of *probable* vascular dementia include the following:

- (a) Early presence of gait disturbance (small-step gait or marche a petits pas, or magnetic, apraxicataxic or parkinsonian gait); (b) history of unsteadiness and frequent, unprovoked falls; (c) early urinary frequency, urgency, and other urinary symptoms not explained by urologic disease;
   (d) pseudobulbar palsy; and (e) personality and mood changes, abulia, depression, emotional incontinence, or other subcortical deficits including psychomotor retardation and abnormal executive function.
- III. Features that make the diagnosis of vascular dementia uncertain or unlikely include (a) early onset of memory deficit and progressive worsening of memory deficit and progressive worsening of memory and other cognitive functions such as language (transcortical sensory aphasia), motor skills (apraxia), and perception (agnosia), in the absence of corresponding focal lesions on brain imaging; (b) absence of focal neurological signs, other than cognitive disturbance; and (c) absence of cerebrovascular lesions on brain CT or MRI.

(continued on next page)

<sup>&</sup>lt;sup>1</sup>Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology* 1993 Feb,43(2):250-60.

- IV. Clinical diagnosis of possible vascular dementia may be made in the presence of dementia (section I-1) with focal neurologic signs in patients in whom brain imaging studies to confirm definite CVD are missing; or in the absence of clear temporal relationship between dementia and stroke; or in patients with subtle onset and variable course (plateau or improvement) of cognitive deficits and evidence of relevant CVD.
- V. Criteria for diagnosis of *definite* vascular dementia are (a) clinical criteria for *probable* vascular dementia; (b) histopathologic evidence of CVD obtained from biopsy or autopsy; (c) absence of neurofibrillary tangles and neuritic plaques exceeding those expected for age; and (d) absence of other clinical or pathological disorder capable of producing dementia.
- VI. Classification of vascular dementia for research purposes may be made on the basis of clinical, radiologic, and neuropathologic features, for subcategories or defined conditions such as cortical vascular dementia, subcortical vascular dementia, BD, and thalamic dementia.

The term "AD *with* CVD" should be reserved to classify patients fulfilling the clinical criteria for possible AD and who also present clinical or brain imaging evidence of relevant CVD. Traditionally, these patients have been included with VaD in epidemiologic studies. The term "mixed dementia," used hitherto, should be avoided.

					If P	resent:
		Present	Absent		Primary	Contributing
<mark>10.</mark>	Alcohol-related dementia	$\Box 1$	$\Box 0$	<mark>10a.</mark>	$\Box 1$	$\Box 2$
	Refer to the DSM-IV manual. <sup>1</sup>					
<mark>11.</mark>	Dementia of undetermined etiology	$\Box 1$	$\Box 0$	<mark>11a</mark> .	$\Box 1$	$\Box 2$
	Refer to the DSM-IV manual.					

<sup>&</sup>lt;sup>1</sup>Diagnostic and statistical manual of mental disorders (DSM-IV). 4<sup>th</sup> ed. 1994, Washington, DC: American Psychiatric Association.

#### Frontotemporal Lobar Degeneration: A Consensus on Clinical Diagnostic Criteria (Neary et al., 1998)<sup>1</sup>

**Criteria:** The clinical criteria are set out in lists 1 through 4. The criteria for each of the three major clinical syndromes are divided into sections. The clinical profile statement together with the core clinical inclusion and exclusion features provide the necessary foundation for diagnosis. Additional clinical features, neuropsychological investigation, and brain imaging support the clinical diagnosis. Operational definitions of specific features are outlined later.

**Clinical profile:** This statement (seen in lists 1 through 3) summarizes the neurobehavioral profile necessary to fulfill criteria for diagnosis.

I. Core diagnostic features: These are features (see lists 1 through 3) integral to the clinical syndrome. All features must be present to fulfill the criteria for diagnosis.

#### II. Supportive diagnostic features:

<u>*Clinical*</u>: These are features (see lists 1 through 3) that are not present in all patients, or they may be noted only during one phase of the disease. They are therefore not necessary conditions for diagnosis. Supportive features are characteristic, often with high diagnostic specificity, and their presence adds substantial weight to the clinical diagnosis. The diagnosis becomes more likely when more supportive features are present.

<u>Physical</u>: In each of the clinical syndromes physical signs are few, in contrast to the prominent mental changes. Parkinsonian signs typically emerge only during late disease. The physical features outlined should be regarded as "supportive" rather than as necessary conditions for diagnosis.

<u>Investigations</u>: Formal neuropsychological assessment, EEG, and brain imagine each can provide support for and strengthen the clinical diagnosis. Such investigatory techniques are not available universally, and ought not to be considered a prerequisite for diagnosis. When neuropsychological assessment is performed, the profile of deficits must demonstrate disproportionate executive dysfunction in FTD or disproportionate language/semantic breakdown in PA and SD. With regard to brain imaging, the patterns of abnormality are characteristic, but not seen invariably. For example, prominent atrophy of the temporal lobes is well visualized by high-resolution MRI, but may be undetected by CT. Failure to demonstrate the prototypic appearances on imaging need not result in diagnostic exclusion.

- **III.** Supportive features common to each of the clinical syndromes: These features (see list 4) support but are not a necessary condition for FTLD.
- IV. Exclusion features common to each clinical syndrome:

<u>*Clinical*</u>: All features (see list 4) must be absent. Early severe amnesia, early spatial disorientation, logoclonic speech with loss of train of thought, and myoclonus are features designed to exclude AD.

Investigations: All features should be absent (when the relevant information is available).

V. Relative diagnostic exclusion features: These are features (see list 4) that caution against but do not firmly exclude a diagnosis of FTLD. A history of alcohol abuse raises the possibility of an alcohol-related basis for a frontal lobe syndrome. However, excessive alcohol intake may also occur in FTD patients as a secondary manifestation of social disinhibition or hyperoral tendencies. The presence of vascular risk factors such as hypertension ought to alert investigators to a possible vascular etiology. Nevertheless, such risk factors are common in the general population and may be present coincidentally in some patients.

<sup>&</sup>lt;sup>1</sup>Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 51:1546-54(1998).

								If Present:	
				Present	Absent		Prima		
<mark>12.</mark>			otemporal dementia (behavioral/executive ntia)	□ 1		<mark>12a</mark>		1 🗆 2	
			LIST 1. The Clinical Dia	ignostic Fe	eatures of F	TD			
throu	ugh	out	ofile: Character change and disordered so the disease course. Instrumental functions atively well preserved.						
I. (	Cor	e di	iagnostic features						
	A.	Insi	idious onset and gradual progression						
	B. Early decline in social interpersonal conduct								
(	C.	Ear	ly impairment in regulation of personal co	nduct					
	D.	Ear	ly emotional blunting						
	E.	Ear	ly loss of insight						
II. :	Sur	סמנ	rtive diagnostic features						
	-	-	navioral disorder						
		1.	Decline in personal hygiene and groomir	na					
		2.	Mental rigidity and inflexibility.	.9.					
		3.	Distractibility and impersistence.						
		4.	Hyperorality and dietary changes.						
		5.	Perseverative and stereotyped behavior.						
		6.	Utilization behavior.						
	В.	Spe	eech and language						
		1	Altered speech output:						
			a. Aspontaneity and economy of speecl	h					
			b. Press of speech						
		2.	Stereotypy of speech.						
		3	Echolalia.						
		4.	Perseveration.						
		5.	Mutism.						
	C.	Phy	ysical signs						
		1. 2.	Primitive reflexes. Incontinence.						
		3.	Akinesia, rigidity, and tremor.						
		4.	Low and labile blood pressure.						
	D.	Inv	estigations						
		1.	Neuropsychology: significant impairment amnesia, aphasia, or perceptuospatial di		lobe tests in	the abs	ence of s	severe	
		2.	Electroencephalography: normal on conv	entional El	EG despite o	linically	evident	dementia.	
		3.	Brain imaging (structural and/or functiona abnormality.	al): predom	inant frontal	and/or a	anterior t	emporal	
			(Review List 4 on <mark>page 56</mark> fo	or diagnost	tic exclusio	n criter	ia.)		

Use the following criteria to guide your answer to item 13:

#### Criteria for Primary Progressive Aphasia (PPA) 1, 2

**Descriptive clinical profile:** An aphasic dementia where the language impairment (aphasia) emerges in relative isolation and is the major determinant in the limitation of daily living activities. Perception, memory, personality are relatively preserved initially.

- I. Core diagnostic features: These features are integral to the clinical syndrome.
  - A. Insidious onset and gradual progression.
  - B. Early onset of aphasic disturbance (including any combination of the following)
    - 1. Word-finding pauses.
    - 2. Word comprehension deficits.
    - 3. Syntactic comprehension deficits.
    - 4. Naming impairments.
    - 5. Circumlocutious speech lacking nouns and verbs.
    - 6. Agrammatic speech (abnormal syntax).
    - 7. Pure word deafness.
    - 8. Dysgraphia.
- **II. Supportive diagnostic features:** These features are not present in all patients, but their presence serves further to support the diagnosis.
  - A. Clinical
    - 1. Onset before the age of 65.
    - 2. Dysarthria.
    - 3. Ideomotor apraxia of the limbs.
    - 4. Ideomotor apraxia of buccofacial musculature.
    - 5. Dyscalculia.
    - 6. Mild facial flattening on the side opposite the language dominant hemisphere (usually right face).
    - 7. Asymmetrical upper extremity posturing upon stressed gait on the side opposite the languagedominant hemisphere (usually right arm).
    - 8. Mild rigidity on the side opposite the language-dominant hemisphere (usually right side of body).
  - B. Investigations
    - 1. Neuropsychology: Findings of aphasia and/or anomia in the absence of amnesia, prosopagnosia, associative visual agnosia, apathy, disinhibition. Scores on verbally mediated tests of memory and fluency may be abnormal because of the aphasia.
    - 2. MRI or CT: Perisylvian atrophy that can extend to parietal cortex and/or inferior temporal cortex on the side of language dominance (usually left).
    - 3. PET or SPECT: Asymmetrical hypometabolism in language-dominant hemisphere (usually left).
    - 4. EEG: Asymmetrical slowing in the temporal leads of the language-dominant hemisphere (usually left).

#### III. Exclusionary features

- A. Historical or clinical
  - 1. Abrupt onset.
  - 2. Early amnesia.

(continued on next page)

<sup>&</sup>lt;sup>1</sup> Mesulam M-M. Primary Progressive Aphasia. Ann. Neurol. 2001;49:425-432.

<sup>&</sup>lt;sup>2</sup> Mesulam M-M. Primary progressive aphasia: A language-based dementia. New Eng J Med. 2003;348:1535-1542.

- 3. Early prosopagnosia, visual agnosia.
- 4. Early spatial disorientation.
- 5. Early apathy or disinhibition.
- 6. Early motor neuron disease (if present, assign to relevant primary diagnosis).
- 7. Early major extrapyramidal signs/CBGD (if present, assign to relevant primary diagnosis).
- 8. Cerebellar signs.
- 9. Early eye movement abnormalities.
- 10. Head trauma related to onset.
- B. Investigations
  - 1. Brain imaging consistent with major stroke in the language dominant hemisphere (usually left).
  - 2. Brain imaging showing asymmetrical moderate to severe lacunar stroke in the languagedominant hemisphere (usually left).
  - 3. Brain imaging showing neoplasm or other space occupying lesion in the language-dominant hemisphere (usually left).
  - 4. Brain imaging showing major trauma to language-dominant hemisphere (usually left).

		Present	Absent		If P Primary	resent: Contributing
12 Da	imany nuo grazziva anhazia (anhazia domontia)			13a.	$\Box$ 1	
	imary progressive aphasia (aphasic dementia)			<mark>15a.</mark>		$\Box Z$
	f PPA is present, specify type by checking <u>one</u> box <u>l others</u> "absent"):	below "pres	sent" and			
1)	Progressive nonfluent aphasia	$\Box 1$	$\Box 0$			
	LIST 2. The clinical diagnostic feature	res of prog	gressive nor	nfluent a	phasia	
	<b>profile:</b> Disorder of expressive language is t course. Other aspects of cognition are intact				throughou	t the
. Core	e diagnostic features					
A. Ir	nsidious onset and gradual progression					
	lonfluent spontaneous speech with at least or araphasias, anomia	ne of the fol	lowing: agrar	nmatism,	, phonemic	C
I. Sup	portive diagnostic features					
A. S	peech and language					
1	. Stuttering or oral apraxia.					
2	. Impaired repetition.					
3	. Alexia, agraphia.					
4	. Early preservation of word meaning.					
5	. Late mutism.					
B. B	ehavior					
1	. Early preservation of social skills.					
2	. Late behavioral changes similar to FTD.					
C. P	hysical signs: late contralateral primitive refle	xes, akines	ia, rigidity, ar	nd tremoi	-	
D. Ir	nvestigations					
1	. Neuropsychology: nonfluent aphasia in the disorder.	absence of	severe amn	esia or pe	erceptuos	oatial
2	. Electroencephalography: normal or minor a	symmetric	slowing.			
3	. Brain imaging (structural and/or functional): dominant (usually left) hemisphere.	asymmetri	c abnormality	y predom	inantly aff	ecting
	(Review List 4 on <mark>page 56</mark> fo	or diagnost	ic exclusion	criteria.	)	

		Present	Absent
2)	Semantic dementia – anomia plus word comprehension	□ 1	□ 0
3)	Semantic dementia – agnosic variant	$\Box 1$	$\Box 0$

#### LIST 3. The clinical diagnostic features of semantic aphasia and associative agnosia (SD)

**Clinical profile:** Semantic disorder (impaired understanding of word meaning and/or object identity) is the dominant feature initially and throughout the disease course. Other aspects of cognition, including autobiographic memory, are intact or relatively well preserved.

#### I. Core diagnostic features

- A. Insidious onset and gradual progression
- B. Language disorder characterized by:
  - 1. Progressive, fluent, empty spontaneous speech;
  - 2. Loss of word meaning, manifest by impaired naming *and* comprehension;
  - 3. Semantic paraphasias; and/or
- C. Perceptual disorder characterized by:
  - 1. Prosopagnosia: impaired recognition of identity of familiar faces; and/or
  - 2. Associative agnosia: impaired recognition of object identity.
- D. Preserved perceptual matching and drawing reproduction
- E. Preserved single-word repetition
- F. Preserved ability to read aloud and write to dictation orthographically regular words

#### II. Supportive diagnostic features

- A. Speech and language
  - 1. Press of speech.
  - 2. Idiosyncratic word usage.
  - 3. Absence of phonemic paraphasias.
  - 4. Surface dyslexia and dysgraphia.
  - 5. Preserved calculation.
- B. Behavior
  - 1. Loss of sympathy and empathy.
  - 2. Narrowed preoccupations.
  - 3. Parsimony.
- C. Physical signs
  - 1. Absent or late primitive reflexes.
  - 2. Akinesia, rigidity, and tremor.
- D. Investigations
- E. Neuropsychology
  - 1. Profound semantic loss, manifest in failure of word comprehension and naming and/or face and object recognition.
  - 2. Preserved phonology and syntax, and elementary perceptual processing, spatial skills, and dayto-day memorizing.
- F. Electroencephalography: normal
- G. Brain imaging (structural and/or functional): predominant anterior temporal abnormality (symmetric or asymmetric)

#### (Review List 4 on page 56 for diagnostic exclusion criteria.)

	Present Absent							
	<ul> <li>4) Other (e.g., logopenic, anomic, transcortical, word deafness, syntactic comprehension, □ 1 □ 0 motor speech disorder)</li> </ul>							
	LIST 4. Features common to clinical syndromes of FTLD (extension of Lists 1 through 3)							
Ш.	Supportive features							
	A. Onset before 65 years: positive family history of similar disorder in first-degree relative							
	<ul> <li>Bulbar palsy, muscular weakness and wasting, fasciculations (associated motor neuron disease present in a minority of patients)</li> </ul>							
IV.	Diagnostic exclusion features							
	A. Historical and clinical							
	1. Abrupt onset with ictal events.							
	2. Head trauma related to onset.							
	3. Early, severe amnesia.							
	4. Spatial disorientation.							
	5. Logoclonic, festinant speech with loss of train of thought.							
	6. Myoclonus.							
	7. Corticospinal weakness.							
	8. Cerebellar ataxia.							
	9. Choreoathetosis.							
	B. Investigations							
	<ol> <li>Brain imaging: predominant postcentral structural or functional deficit; multifocal lesions on CT or MRI.</li> </ol>							
	<ol> <li>Laboratory tests indicating brain involvement of metabolic or inflammatory disorder such as MS, syphilis, AIDS, and herpes simplex encephalitis.</li> </ol>							
۷.	Relative diagnostic exclusion features							
	A. Typical history of chronic alcoholism							
	B. Sustained hypertension							
	C. History of vascular disease (e.g., angina, claudication)							

For subjects with normal cognition, indicate whether the following conditions are present or absent. If the subject is cognitively impaired, indicate also whether the condition is primary, contributing or non-contributing to the observed cognitive impairment, based on your best judgment. As an example, if subject is cognitively impaired and the impairment is due to Parkinson's disease dementia, then mark item #23 as "Present" and item #23a as ""Primary". If subject has other co-morbid conditions, these should be indicated as well. Mark only <u>one</u> condition as primary.

							If Present:	
		Present	Absent			Primary	Contributing	Non- contrib.
14. Progre	essive supranuclear palsy	$\Box 1$	$\Box 0$		<mark>14a.</mark>	$\Box$ 1	$\Box 2$	□ 3
Use the following criteria, excerpted from <i>SIC Task Force Appraisal of</i> <i>Clinical Diagnostic Criteria for Parkinsonian Disorders</i> (Litvan et al., 2003): <b>NINDS-SPSP clinical criteria for the diagnosis of PSP</b>								
Diagnostic				agriosis				
categories	Inclusion criteria	Exclusion criteria Supportive criteria						
	For possible and probable: Gradually progressive disorder with age at onset at 40 or later;	Recent hi alien limb sensory d or tempor hallucinat unrelated therapy; c Alzheimer early cere unexplain evidence	ble and pro story of end syndrome; eficits; foca oparietal at ions or delu to dopamin ortical dem r type; prom bellar symp ed dysauto of other dis explain the	cep co al f rro usi ner ner no co co co co co co co co co co co co co	ohalitis; ortical rontal phy; ons rgic ntia of tia of tia of tia of tias or oms or omia; or ases	proximal abnorma especial absent r parkinso early dys early ons impairma apathy, i thought, fluency,	ric akinesia or I more than di al neck postur ly retrocollis; p esponse of onism to levod sphagia & dys set of cognitiv ent including s impairment in decreased ve utilization or in r, or frontal rel	stal; e, boor or opa; arthria; e > 2 of: abstract erbal mitation
Possible	Either vertical supranuclear palsy or both slowing of vertical saccades & postural instability with falls < 1 yr disease onset.							
Probable	Vertical supranuclear palsy and prominent postural instability with falls within first year of disease onset. <sup>a</sup>							
Definite All criteria for possible or probable PSP are met and histopathologic confirmation at autopsy.								
Adapted fro	m Litvan et al., 1996 <sup>1</sup>							
<sup>a</sup> Later defin	ned as falls or the tendency to	fall (patients	s are able t	0 5	stabilize	themselve	s).	
Supranucle	SP = National Institute of Neuro ar Pals, Inc.	ological Dis	orders and	St	roke, an	d Society	for Progressiv	e

PSP = progressive supranuclear palsy.

<sup>&</sup>lt;sup>1</sup>Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report on the NINDS-SPSP international workshop. Neurology 1996;47:1-9.

							If Present:		
		Present	Absent	t		Primary	Contributing	Non- contrib.	
15. Corticob	asal degeneration	$\Box$ 1	$\Box 0$		<mark>15a.</mark>	$\Box 1$	$\Box 2$	□ 3	
	Use the following criteria, excerpted from <i>SIC Task Force Appraisal of Clinical Diagnostic Criteria for</i> <i>Parkinsonian Disorders</i> (Litvan et al., 2003) <sup>1</sup> : <b>Proposed research criteria for CBD</b>								
Diagnostic									
categories	Inclusion crite				Exclusion				
Lang et al <sup>2</sup>	Rigidity plus one cortical s cortical sensory loss, or al <i>Or</i> Asymmetric rigidity, dystor reflex myoclonus.	lien limb)	tre su I or	emor; ustaine	severe ed respo jing stud	autonomic	ical gaze pals disturbances to levodopa; ting another p	lesions	
Kumar et al <sup>3</sup>									
CBD = corticobasal degeneration. Qualification of clinical features: rigidity, easily detectable without reinforcement; apraxia, more than simple use of limb as an object, clear absence of cognitive or motor deficit; cortical sensory loss, asymmetric, with preserved primary sensation; alien limb phenomenon, more than simple levitation; dystonia, focal in limb, present at rest at onset; myoclonus, reflex myoclonus spreading beyond stimulated digits.									
	t at onset; myoclonus, reflex	x myoclonus	spread		yond st	imulated d	igits.	n limb,	
	t at onset; myoclonus, reflex								
	t at onset; myoclonus, reflex	x myoclonus	spread		yond st	imulated d	igits.	n limb,	
	t at onset; myoclonus, reflex on's disease the DSM-IV manual.	x myoclonus	spread		yond st	imulated d	igits.	n limb,	
Refer to	t at onset; myoclonus, reflex on's disease the DSM-IV manual.	x myoclonus	spread		yond st	imulated d	igits.	n limb,	
Refer to 17. Prion dis Refer to	t at onset; myoclonus, reflex on's disease the DSM-IV manual. ease the DSM-IV manual. e dysfunction from	x myoclonus	spread		yond st	imulated d	igits.	n limb,	
Refer to 17. Prion dis Refer to 18. Cognitiv medication	t at onset; myoclonus, reflex on's disease the DSM-IV manual. ease the DSM-IV manual. e dysfunction from	x myoclonus	spread		16a. 17a.	□ 1		n limb,	
Refer to 17. Prion dis Refer to 18. Cognitiv medication Refer to	t at onset; myoclonus, reflex on's disease the DSM-IV manual. ease the DSM-IV manual. e dysfunction from ons	x myoclonus	spread		16a. 17a.	□ 1		n limb,	

<sup>&</sup>lt;sup>1</sup>Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003 May; 18(5):467-86.

<sup>&</sup>lt;sup>2</sup>Lang AE, Riley DE, Bergeron C. Cortico-basal ganglionic degeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: WB Saunders; 1994. p 877-894.

<sup>&</sup>lt;sup>3</sup>Kumar R, Bergeron C, Pollanen MS, Lang AE. Cortical basal ganglionic degeneration. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams and Wilkins; 1998. p 297-316.

							If Present:	Non-	
		Present	Absent			Primary	Contributing	contrib.	
). D	Depression	$\Box$ 1	$\Box 0$		<mark>20a.</mark>	$\Box 1$	$\Box 2$	□ 3	
	OSM-IV <sup>1</sup> criteria as summarized in <sup>*</sup> Columbia University for the Alzheim					dures Mar	nual (created l	ру	
1	. At least one of the following three life:	e abnormal	moods that	t si	gnificant	ly interfere	ed with the pe	rson's	
	a. Abnormal depressed mood most of the day, nearly every day, for at least 2 weeks.								
	b. Abnormal loss of all interest and pleasure most of the day, nearly every day, for at least 2 weeks.								
	<ul> <li>c. If 18 or younger, abnormal irr weeks.</li> </ul>	itable mood	most of the	e d	ay, near	ly every da	ay, for at least	: 2	
2	2. At least five of the following symptoms have been present during the same 2-week depressed period:								
	a. Abnormal depressed mood (or irritable mood if a child or adolescent), as defined in 1a.								
	b. Abnormal loss of all interest and pleasure, as defined in 1b.								
	c. Appetite or weight disturbance, either:								
	1) Abnormal weight loss (whe	en not dietin	g) or decre	as	e in app	etite; or			
	2) Abnormal weight gain or ir	ncrease in a	ppetite.						
	d. Sleep disturbance, either abn	ormal inson	nnia or abn	orr	nal hype	rsomnia.			
	e. Activity disturbance, either ab	normal agita	ation or abr	nor	mal slov	ving (obse	rvable by othe	ers).	
	f. Abnormal fatigue or loss of er	nergy.							
	g. Abnormal self-reproach or ina	appropriate o	guilt.						
	h. Abnormal poor concentration	or indecisiv	eness.						
	i. Abnormal morbid thoughts of	death (not j	ust fear of	dyi	ng) or si	uicide.			
3	3. The symptoms are not due to a r	mood-congr	uent psych	osi	s.				
4	. There has never been a Manic E	pisode, a N	lixed Episo	de	, or a Hy	pomanic I	Episode.		
5	5. The symptoms are not due to ph	ysical illnes	s, alcohol,	me	dication	, or street	drugs.		
6	5. The symptoms are not due to no	rmal bereav	vement.						

<sup>&</sup>lt;sup>1</sup> Diagnostic and statistical manual of mental disorders (DSM-IVE). 4<sup>th</sup> ed. 1994, Washington, DC: American Psychiatric Assoc.

				]			If Present:	N		
	Pre	esent	Absent			Primary	Contributing	Non- contrib.		
21. Other major psychiatric illness		] 1	$\Box 0$		<mark>21a</mark>	<mark></mark> □ 1	$\Box 2$	□ 3		
Refer to the DSM-IV manual.										
22. Down's syndrome		] 1	$\Box 0$	]	<mark>22a</mark>	L. □1	□ 2	□ 3		
Refer to the DSM-IV manual.										
23. Parkinson's disease		] 1	$\Box 0$	]	<mark>23a</mark>	L. □1	$\Box 2$	□ 3		
Use the following criteria, excerpted from <i>SIC Task Force Appraisal of Clinical Diagnostic Criteria for Parkinsonian Disorders</i> (Litvan et al., 2003). [These are the suggested criteria included in the most recent AAN Practice Parameter; the UDS "Instructions for Neuropsychological Tests (Form C1)" will include the Practice Parameter as soon as it is published]:										
UK Parkinson's Dis	1				nical			-		
Inclusion criteria		xclusio					pportive crite			
Bradykinesia (slowness of initiation of voluntary movement	History of stepwi	ise progr			itn		more required of definite PD			
with progressive reduction in speed and amplitude of repetitive	parkin	parkinsonian features.					Unilateral onset.			
actions);	History of			•	•	Rest tre	Rest tremor present.			
And at least one of the following:	History of		encepha	litis	s.	Progres	Progressive disorder.			
Muscular rigidity.		culogyric crises. euroleptic treatment at onset of					Persistent asymmetry affecting			
4–6 Hz rest tremor.	Neurolepi sympt		ient at oi	nse	et of		side of onset most.			
Postural instability not caused by primary visual, vertibular,	More than	Nore than one affected relative.					Excellent response (70–100%) to levodopa.			
cerebellar, or proprioceptive		Sustained remission.					Severe levodopa-induced			
dysfunction.	Strictly un			afte	er 3 yr					
	Supranuc	-	e paisy.			Levodopa response for 5 yr o more.				
	Early sev	Cerebellar signs. Early severe autonomic				Clinical course of 10 yr or more.				
	Early sevents disturb	involvement. Early severe dementia with disturbances of memory, language, and praxis.								
	Babinski	Babinski sign.								
	comm	resence of cerebral tumour or communicating hydrocephalus on CT scan.								
	Negative of leve exclue	odopa (if	-							
	MPTP ex	posure.								
UK = United Kingdom; PD = Parkins	son's diseas	se; CT =	compute	ed t	tomog	raphy.				

The following information, published as Tables 10 and 11 in the *SIC Task Force Appraisal of Clinical Diagnostic Criteria for Parkinsonian Disorders* (Litvan et al., 2003)TP<sup>1</sup>PT, may be useful for differential diagnosis of non-Alzheimer's dementia.

Clinical domain	Features	Criteria
Autonomic and urinary dysfunction	Orthostatic hypotension (by 20 mm Hg systolic or 10 mm Hg diastolic); urinary incontinence or incomplete bladder emptying. <sup>a</sup>	Orthostatic fall in blood pressure (by 30 mm Hg systolic or 15 mm Hg diastolic) and/or urinary incontinence (persistent, involuntary partial or total bladder emptying, accompanied by erectile dysfunction in men). <sup>a</sup>
Parkinsonism	B, R, I, and T.	1 of 3 (R, I, and T) and B.
Cerebellar dysfunction	Gait ataxia; ataxic dysarthria; limb ataxia; sustained gaze-evoked nystagmus.	Gait ataxia plus at least one other feature.
Corticospinal tract dysfunction	Extensor plantar responses with hyperreflexia.	No corticospinal tract features are used in defining the diagnosis of MSA. <sup>b</sup>

Table 1. Consensus Criteria for the Diagnosis of MSA

MSA = multiple system atrophy; B = bradykinesia; R = rigidity; I = postural instability; T = tremor.

<sup>a</sup> Note the different figures for orthostatic hypotension, depending on whether it us used as a feature or a criterion.

<sup>b</sup> In retrospect, this criterion is ambiguously worded. One possible interpretation is that, while corticospinal tract dysfunction can be used as a *feature* (characteristic of the disease), it cannot be used as a *criterion* (defining feature or composite of features required for diagnosis) in defining the diagnosis of MSA. The other interpretation is that corticospinal tract dysfunction cannot be used at all in consensus diagnostic criteria, in which case there is no point mentioning it.

Table 2.	Consensus	Diagnostic	Categories	and Exclusion	Criteria for MSA
I GOIC II	Compensar	Linghostic	Categories	which increasion	

Diagnostic categories	Inclusion criteria	Exclusion criteria			
Possible	One criterion plus two features from separate other domains. When the criterion is parkinsonism, a poor levodopa response qualifies as one feature (hence, only one additional feature is required).	<ul> <li>For possible and probable:</li> <li>Symptomatic onset &lt;30 yrs of age;</li> <li>Family history of a similar disorder;</li> <li>Systemic diseases or other identifiable causes for features listed in Table 1;</li> </ul>			
Probable	One criterion for autonomic failure/urinary dysfunction plus poorly levodopa responsive parkinsonism or cerebellar dysfunction.	Hallucinations unrelated to medication; DSM criteria for dementia; Prominent slowing of vertical saccades or			
Definite	Pathologically confirmed by the presence of a high density of glial cytoplasmic inclusions in association with a combination of degenerative changes in the nigrostriatal and olivopontocerebellar pathways.	<ul> <li>vertical supranuclear gaze palsy;</li> <li>Evidence of focal cortical dysfunction such as aphasia, alien limb syndrome, and parietal dysfunction;</li> <li>Metabolic, molecular genetic, and imaging evidence of an alternative cause of features listed in Table 1.</li> </ul>			

MSA = multiple system atrophy; DSM = Diagnostic and Statistical Manual for Mental Disorders.

<sup>&</sup>lt;sup>1</sup>Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003 May; 18(5):467-86.

							If Present:		
		Present	Absent			Primary	Contributing	Non- contrib.	
<mark>24.</mark>	Stroke	$\Box 1$	$\Box 0$		<mark>24a.</mark>	□ 1	$\Box 2$		
	Use the following criteria <sup>1</sup> for stroke	and recode	either of tv	vo	categor	<mark>ies as "pre</mark>	esent":		
	Clinical Stroke Rapidly developing clinical symptoms and/or signs of focal and at times global loss of cerebral function (applied to patients in deep coma and to those with subarachnoid hemorrhage) with symptoms lasting more than 24 hours or leading to death (therefore excluding transient ischemic attacks), and with no apparent cause other than vascular.								
	Patients are classified as having an ischemic stroke if they had computed tomographic or magnetic resonance imaging of the brain done within 7 days of onset of symptoms that either identified the symptomatic cerebral infarct or failed to identify an alternative cause of the symptoms.								
	Silent Stroke However, strokes determined by ne "silent stroke") should be captured b participants have the necessary ima UDS form. For this question, a silen	by the UDS.	This captu available at	re th	will be lo e time t	ess than 1 he cliniciar	00% as not al	I ADC	
<mark>25.</mark>	Hydrocephalus	□ 1			<mark>25a.</mark>	□ 1	□ 2		
	Self-explanatory.								
<mark>26.</mark>	Traumatic brain injury	$\Box$ 1	$\Box 0$		<mark>26a.</mark>	□ 1	$\Box 2$	□ 3	
	Self-explanatory.								
<mark>27.</mark>	CNS neoplasm	□ 1	$\Box 0$		<mark>27a.</mark>	□ 1	$\Box 2$		
	Self-explanatory.								
<mark>28.</mark>	Other ( <i>specify</i> ):	□ 1			<mark>28a.</mark>	□ 1	□ 2	□ 3	
29.	Other ( <i>specify</i> ):				<mark>29a.</mark>		□ 2	<mark>□ 3</mark>	
<mark>30.</mark>	Other ( <i>specify</i> ):		<mark>□ 0</mark>		<mark>30a.</mark>	□ 1	<mark>□ 2</mark>	<mark>□ 3</mark>	
	If there is an observed cognitive imp this category as "present", enter the or non-contributing.								

<sup>&</sup>lt;sup>1</sup>Cerebrovascular disease in the community: Results of a WHO Collaborative Study. (S Aho et al., 1980, Bull World Health Org., 58:113-130).

## Form E1: IMAGING/LABS

The purpose of this form is to record any imaging or tests performed during the subject's current visit or previous visits, from which images or samples are available. The form should be completed by ADC or clinic staff.

Neuroimaging available at your ADC:			Film Yes No			Digita Yes	l image No
1.	Computed tomography	1a.	$\Box 1$	$\Box 0$	1b.	□ 1	$\Box 0$
2.	Magnetic resonance imaging – Clinical study	2a.	□ 1	$\Box 0$	2b.	□ 1	$\Box 0$
3.	Magnetic resonance imaging – Research study/structural	3a.	□ 1		3b.	□ 1	
4.	Magnetic resonance imaging – Research study/functional	4a.	□ 1		4b.	□ 1	
5.	Magnetic resonance spectroscopy	5a.	□ 1	$\Box 0$	5b.	□ 1	$\Box 0$
6.	SPECT	ба.	□ 1	$\Box 0$	6b.	□ 1	$\Box 0$
7.	PET	7a.	$\Box 1$	$\Box 0$	7b.	$\Box$ 1	$\Box 0$
	If neuroimaging was performed and the files/data are available at your ADC, check "yes".						

Specimens available at your ADC:	Yes	No				
8. DNA	$\Box$ 1	$\Box 0$				
9. Cerebrospinal fluid – ante-mortem	□ 1	$\Box 0$				
10. Serum/plasma	□ 1	$\Box 0$				
If specimens were collected and available at your ADC, check "yes".						

Genotyping results:	Yes	No			
11. APOE genotype collected	$\Box 1$	$\Box 0$			
If APOE genotyping has been performed and the slides/files/data are available at your ADC, check "yes".					